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Abstract 
EFFECTS OF EMPHYSEMA AND CHRONIC HYPOXEMIA ON SKELETAL 
MUSCLE OXYGEN SUPPLY AND DEMAND 
By John D. Lowman Jr., Ph.D., P.T., C.C.S. 
A dissertation submitted in partial fulfillment of the requirements for the Doctor of 
Philosophy degree at the Medical College of Virginia Campus, Virginia Commonwealth 
University. 
Virginia Commonwealth University, 2004 
Major Director:  Dr. Roland N. Pittman, Professor, Department of Physiology 
 
Skeletal muscle dysfunction in chronic obstructive pulmonary disease (COPD) is a 
condition in which peripheral skeletal muscle undergoes myopathic changes which 
impair muscle function, limit physical performance, and can lead to significant disability.  
While the etiology of the dysfunction is unknown, this study was conducted to test the 
hypothesis that chronic hypoxemia leads to alterations in oxygen transport and muscle 
function.  A primary objective was to validate elastase-induced emphysema in rats as an 
animal model of skeletal muscle dysfunction in COPD. 
Arterial blood gases were used to determine the severity of hypoxemia and sodium 
dodecyl sulfate- polyacrylamide gel electrophoresis was used to determine the 
proportions of myosin heavy chain isoforms I, IIa, IIx, and IIb.  Measures of 
   xxviii 
 
microvascular oxygenation and blood flow in the spinotrapezius muscle allowed for 
determination of both convective and diffusive oxygen supply to the muscle, as well as 
calculation of muscle oxygen consumption at rest and during electrically stimulated 
three-minute muscle contractions.  Muscle performance measures included peak force, 
force-time integral, and fatigue index.  
Due to a presumed rat respiratory virus, which likely resulted in the control group being 
nearly as hypoxemic as the elastase-induced emphysema group, this study was not able to 
definitively test the hypothesis that chronic hypoxemia leads to both a diminished supply 
and demand of oxygen in skeletal muscle.  Although many of the results of the present 
study were not statistically significant, they exhibited consistent trends over time and are 
likely of physiological significance.  All measures of muscle performance were lower in 
the emphysema group.  In addition, spinotrapezius muscle oxygen consumption and 
blood flow were lower in the emphysema group.  The addition of supplemental oxygen 
during isolated, small-muscle mass exercise did increase the force-time integral by ~18% 
in both groups, suggesting that muscle work in these hypoxemic animals may be limited 
by oxygen supply.   
Thus, the data on muscle fiber type, oxygen consumption and muscle performance 
suggest that elastase-induced emphysema in rats leads to a similar skeletal muscle 
dysfunction that is observed in humans with COPD, and indicates that it is a valid animal 
model of skeletal muscle dysfunction in COPD. 
 
   1 
Introduction 
 
COPD:  definition and epidemiology 
Chronic obstructive pulmonary disease (COPD), an umbrella term that primarily refers to 
emphysema and chronic bronchitis (West 1997), is the fourth leading cause of death in 
the U.S. (Anderson 2001), accounts for 1.7% of ambulatory care visits (NCHS 1999), and 
costs an estimated $30.4 billion per year (ALA 2001).  While the overall death rate in the 
past 20 years has decreased 18%, COPD mortality has increased 42% (ALA 2001).  The 
death rate is even higher in mountainous high-altitude states where the partial pressure of 
inspired oxygen (PIO2) is lower (Anderson 2001); however, oxygen therapy, which 
increases PIO2, also increases exercise tolerance and quality of life, and decreases dyspnea 
(shortness of breath) and mortality in chronically hypoxemic patients (NOTTG 1980; 
Eaton, Garrett et al. 2002). 
Hypoxia vs. hypoxemia:  definition and causes 
Hypoxia refers to low oxygen (O2) levels in general, and is often preceded by adjectives 
that describe its location:  alveolar hypoxia, tissue hypoxia, or cellular hypoxia.  Cellular 
hypoxia is functionally defined as the failure of convective or diffusive O2 transport to 
meet the O2 demand such that the rate of adenosine triphosphate (ATP) synthesis is 
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limited.  Hypoxia can also be defined in terms of its etiology:  1) ischemic hypoxia, due 
to blood-flow limitations, 2) anemic hypoxia, due to low hemoglobin concentrations, 3) 
histotoxic or cytotoxic hypoxia, due to chemical poisoning of the cell, and 4) hypoxic 
hypoxia, due to hypoxemia (Schumacker 1991). 
Specifically, hypoxemia refers to a decreased arterial oxygen partial pressure (PaO2) 
below the normal range (80-100 mmHg) (Pierson 2000).  Obviously, hypoxemia can be a 
cause of tissue or cellular hypoxia.  Hypoxemia can be caused by:  1) hypoventilation, 2) 
impaired diffusion across the alveolar blood-gas barrier, 3) ventilation-perfusion 
mismatch, 4) intrapulmonary shunt, or 5) breathing a reduced PIO2 (West 1997). 
Clinically, acute hypoxemia refers to a short-term (minutes to days), reversible cause of 
hypoxemia (i.e., a patient recovering from pneumonia or anesthesia), while chronic 
hypoxemia is a longer-term process (days to decades) and the cause is usually irreversible 
(i.e., a patient with COPD or pulmonary fibrosis).  Chronic hypoxemia in COPD is 
primarily caused by ventilation-perfusion mismatch (ventilation of under perfused lung 
tissue and/or perfusion of under ventilated lung tissue), but also by impaired diffusion 
(decreased surface area available for gas exchange due to destruction of alveoli) and 
hypoventilation (decreased minute ventilation due to an increased work of breathing) 
(West 1998).  
Research on “chronic hypoxia” is usually based on human or animal studies lasting less 
than three months, what I shall refer to as “short-term chronic hypoxia.”  Studies using 
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patients with COPD or permanent high-altitude residents will be referred to as “long-term 
chronic hypoxia.”  In most of these studies, the term hypoxia is used as opposed to 
hypoxemia, because there were no measures to verify a low PaO2.   
Skeletal muscle dysfunction in COPD 
COPD results not only in impaired pulmonary function, but also well known 
cardiovascular sequelae:  pulmonary hypertension and right ventricular hypertrophy.  In 
addition, there are more poorly understood secondary effects on skeletal muscle, such as 
impaired muscle strength and endurance.  These impairments result in dyspnea (shortness 
of breath), leg fatigue, and poor exercise tolerance (Zattara-Hartmann, Badier et al. 1995; 
Serres, Gautier et al. 1998), and are the symptoms of the emerging syndrome “Skeletal 
muscle dysfunction in COPD” (ATS/ERS 1999). 
Skeletal muscle dysfunction in COPD is a debilitating disease that often leaves patients 
anxious, homebound, and depressed because of their poor tolerance for physical activity, 
including basic activities of daily living.  A significant amount of research has focused on 
characterizing this syndrome over the last 25 years, much of which will be reviewed 
subsequently.  The etiology of skeletal muscle dysfunction in COPD is unknown, but the 
most likely causes include hypercapnia, inflammation, malnutrition, deconditioning 
(decline in physical performance due to inactivity), and hypoxemia.  The evidence seems 
to favor deconditioning and/or hypoxemia (Richardson 1999), but uncoupling the two has 
proved difficult in human studies.   
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Oxygen transport in normal skeletal muscle 
Oxygen transport to skeletal muscle by blood is regulated by adjusting O2 supply (cardiac 
output, blood flow distribution, and the O2 capacity of the blood) to the O2 demand 
(metabolic consumption) of the muscle (Weibel 1984).  As far as O2 supply goes, I will 
focus on blood flow distribution to and in skeletal muscle, and O2 capacity of the blood; 
for the current discussion it is sufficient to say that cardiac output generally increases as 
oxygen consumption increases.   
Oxygen supply 
Oxygen supply, or delivery, consists of both convective and diffusive flow of O2.  
Convective delivery refers to the bulk flow of O2 bound to hemoglobin (Hb) in red blood 
cells (RBCs) from the lung’s microvascular network (O2 source) to the muscle’s 
microvascular network via the cardiovascular system, while diffusive delivery refers to 
the flux of O2 out of the RBCs in the microcirculation to the mitochondria (O2 sink) in 
the muscle fibers (Pittman 2000). 
Convective O2 delivery 
Based on Fick’s Principle, whole body convective O2 delivery ( COQ 2
 ) is: 
Equation 1 
22
O
C
O aCQQ ⋅=   
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where Q  is total blood flow (cardiac output) and 2OaC  is arterial O2 content (Pittman 
2000).  Tissue perfusion, and thus convective O2 delivery, is regulated by both total blood 
flow and blood flow distribution.  Altering blood flow distribution in response to changes 
in local metabolism allows the fraction of cardiac output increase to metabolically active 
tissues, while shunting blood away from less metabolically active tissue, and is altered by 
modulating vascular resistance, which is under both neural and local regulation (Weibel 
1984).   
Diffusive O2 delivery 
Diffusive O2 delivery ( DOQ 2
 ) is related to convective O2 delivery ( COQ 2 ) by: 
Equation 2 
)()(
222
out
C
Oin
C
O
D
O QQQ  −=  
where )(
2
in
C
OQ  and )(2 outCOQ are the convective flow of O2 into and out of the muscle tissue, 
respectively (Pittman 2000).  Equation 2 is related to Fick’s first law of diffusion that can 
be expressed as: 
Equation 3 
rPADQ OOODO ∆∆⋅⋅⋅= /2222 α  
where 2OD  and 2Oα  are the diffusion and solubility coefficients for oxygen, A is the 
available surface area for diffusion, and rPO ∆∆ /2  is the radial PO2 gradient (Pittman 
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2000).  As indicted by Equation 3, O2 will diffuse from one site to another provided the 
driving force (∆PO2 = blood PO2 – intracellular PO2) is large enough and the diffusion 
distance (∆r) is not too great.  In fact, contrary to traditional views, Swain and Pittman 
(1989) calculated that, in the hamster retractor muscle, about ⅔ of DOQ 2
  occurs in the 
arterioles and about ⅓ in the capillaries. 
DO2 and αO2 are relatively constant.  However, if the number of perfused capillaries per 
muscle fiber area increases, then A increases and diffusion distance decreases, causing O2 
flux to increase.  Diffusion distance can also be altered by changing the quantity and 
location (subsarcolemmal vs. intermyofibrillar) of mitochondria, the O2 sink, in the 
muscle (Weibel 1984).  The other way to increase O2 flux is by increasing ∆PO2; this can 
occur by:  1) shifts in the oxy-hemoglobin (Hb-O2) dissociation curve, 2) myoglobin 
facilitated diffusion, and 3) increased consumption (see next section:  Oxygen demand). 
The Hb-O2 dissociation curve (Figure 1) can shift to the left or right by changes in 1) 
muscle temperature, 2) carbon dioxide tension/pressure (PCO2), 3) hydrogen ion 
concentration [H+], and 4) 2,3-diphosphoglycerate concentration [2,3-DPG] (Berne and 
Levy 1998).  Exercise, or muscular work, increases the first three of these factors, 
shifting the curve to the right, which facilitates a higher blood PO2 for a given O2 
saturation (SO2) of hemoglobin and enhances O2 flux by increasing ∆PO2. 
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Figure 1. Hemoglobin-O2 dissociation curve (P50 = 36 mmHg). 
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Myoglobin (Mb) facilitated diffusion increases O2 flux by several mechanisms.  By 
binding free O2 inside the muscle fiber, myoglobin lowers subsarcolemmal PO2, thus 
increasing ∆PO2 and enhancing O2 flux.  Myoglobin binding of O2 inside the fiber 
decreases the diffusion distance for free O2.  Lastly, due to the shape of the Mb-O2 
dissociation curve (Figure 2) (Schenkman, Marble et al. 1997), myoglobin also buffers 
mitochondrial PO2 by releasing bound O2 as intracellular PO2 decreases, which occurs 
during muscle contraction as O2 is consumed, and intramuscular pressure compresses 
blood vessels and impairs convective O2 supply (Honig, Gayeski et al. 1991).   
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Figure 2. Myoglobin-O2 dissociation curve (P50 = 2.4 mmHg). 
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Oxygen demand 
Within the mitochondria, the process of oxidative phosphorylation consumes O2 in 
proportion to the need to produce ATP and replenish high energy phosphate stores within 
the muscle.  This O2 consumption by the mitochondria depletes cellular O2 stores, lowers 
intracellular PO2, increases ∆PO2 and results in increased O2 demand.  In skeletal muscle, 
O2 consumption (
2O
V ) can vary from 1.7 ml/min/kg at rest to over 70 ml/min/kg at 
2O
V max (Weibel 1984; Aw and Jones 1990).  This dramatic range of 
2O
V  requires 
complex regulation of the O2 supply, but also provides a reserve capacity that is rarely 
utilized.  Due to this large 
2O
V  reserve capacity as well as the ability of the muscle to 
increase oxygen extraction, minor impairments in O2 supply do not pose a major threat to 
the organism under normal functional conditions (i.e., the muscle tissue does not become 
hypoxic).  However, a major impairment in O2 supply (i.e., chronic hypoxemia) does 
result in muscle tissue hypoxia, which has both cellular and systemic effects. 
Effect of COPD and chronic hypoxemia on skeletal muscle 
The effects of chronic hypoxemia on skeletal muscle are evident not only by cellular 
changes within the muscle fibers themselves, but also include systemic effects, including 
increased RBC production and microvascular changes.  In the following literature 
review, hypoxemia is the result of either 1) chronic lung disease, or 2) reduced PIO2.  PIO2 
can be reduced by 1) lowering the fraction of inspired O2 (FIO2) below that of room air 
(0.21), and/or 2) decreasing the barometric pressure ((PB) hypobaric hypoxia); PB can be 
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lowered in the lab using a hypobaric chamber or in the field by going to high altitudes 
(normal PIO2 of room air at sea level is 150 mmHg). 
Muscle fiber changes 
Muscle fiber type 
Specific muscle fiber types have been classified using several schemes.  One of the first 
was based on contractile speed (time-to-peak tension) and fatigability:  slow-twitch, 
fatigue resistant (S), fast-twitch, fatigue resistant (FR), fast-twitch, intermediate 
fatigability (FI), and fast-twitch, fatigable (FF) (Burke, Levine et al. 1971).  There are 
two histochemical methods, one based on metabolic enzyme staining:  slow-twitch 
oxidative (SO), fast-twitch oxidative, glycolytic (FOG), and fast-twitch glycolytic (FG) 
(Peter, Barnard et al. 1972), and the other based on pH lability of myofibrillar adenosine 
triphosphatase (ATPase) staining:  I, IIa, IIx, and IIb (Brooke and Kaiser 1970).  More 
recently, myosin heavy chain (MHC) immunoreactivity has been developed using 
specific antibodies for different MHC isoforms:  I, IIa, IIx, and IIb (Termin, Staron et al. 
1989).  Refer to Table 1 for a summary of how the classifications schemes compare. 
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Table 1.  Muscle-fiber type classification schemes. 
 
 
 
 
Classification 
Scheme 
Muscle-Fiber Type 
Twitch S FR FI FF 
Metabolic SO FOG  FG 
ATPase I IIa IIx IIb 
MHC I IIa IIx IIb 
modified from ATS/ERS (1999)  
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The proportion of muscle fiber types from the vastus lateralis muscle of asymptomatic 
elderly men is:  48% type I, 34% type IIa, and 17% type IIb.  It varies slightly for 
women:  54% type I, 41% type IIa, and 7% type IIb, but was only significantly different 
for type IIb (due to rounding, these values total slightly more or less than 100%) 
(Aniansson, Grimby et al. 1981).  These numbers serve as reference values for the 
ensuing discussion of fiber types in COPD, primarily a disease of the aged.   
In a group of 18 patients with advanced COPD, with and without hypercapnia (PaCO2 > 
40 mmHg), Jakobsson et al (1990) looked at the percentage of type I muscle fibers in the 
vastus lateralis and found that patients with and without hypercapnia had abnormally low 
percentages of type I fibers, 17 and 22% respectively, which were positively correlated to 
PaO2, 58 and 78 mmHg, respectively, and were more than 50% lower than reference 
values.  A similar finding of decreased proportion of type I fibers, 29%, was found in 
nine patients with a PaO2 of 63 mmHg (Hildebrand, Sylven et al. 1991).  More recently, 
Satta et al (1997) used the MHC classification in 22 borderline hypoxemic (mean PaO2 = 
81 mmHg) patients with COPD (mean age 65).  They reported a fiber transformation 
from MHC I to MHC II2A to MHC2B, and in particular report a MHC2B proportion of 
23% versus 7% for their control group (mean age 35).  Using age matched controls (mean 
age 65), Whittom et al (1998) also reported reduced type I and increased type IIb fibers 
in patients with COPD.  Even following lung transplantation (mean postoperative months 
= 12, range 3 to 24), essentially curing hypoxemia, patients continue to have a lower 
proportion of type I fibers, 25% vs. 56% for control (Wang, Williams et al. 1999).   
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Contrary to the consistent evidence of fiber type transformation in patients with COPD, 
the data are less conclusive regarding normal subjects exposed to hypobaric hypoxia.  A 
study of permanent, high-altitude residents (PIO2 ~90 mmHg), who did not regularly 
exercise, found normal fiber type proportions:  type I 50.8%, type IIa 30.3%, type IIb 
15.4%, and 2.9% type IIab (Desplanches, Hoppeler et al. 1996).  Green et al studied 
mountaineers exposed to eight weeks of high altitude (5,000-8,484 m; PIO2 = 43-78 
mmHg) and saw no change in fiber-type distribution (Green, Sutton et al. 1989).  
However, in a later study he reported a 12% decrease in type I and a corresponding 
increase in type IIa and IIb fibers following only three weeks at 4,300 m (PIO2 = 88 
mmHg) (Green, Sutton et al. 1992). 
Animal models of hypoxia are not conclusive either.  Although Itoh et al (1990) found a 
decrease in type I and increase in type II muscle fibers of rats exposed to 10 weeks at 
4,000 m (PIO2 = 91 mmHg), Takahashi et al (1992) saw no fiber type transformation in 
rats exposed to PIO2 of 71 mmHg for four weeks, a relatively short hypoxic period.  van 
Ekeren et al (1992), using a more pronounced hypoxia (PIO2 = 57 mmHg) in rats for 
almost seven weeks, also reported no change in fiber type proportions.   
Muscle mass/Cross sectional area 
Muscle tissue mass and fiber cross-sectional area (FCSA) provide indices of muscle force 
production or strength (Lieber 1992).  Since a loss in lower extremity strength is a 
hallmark of skeletal muscle dysfunction in COPD (Hamilton, Killian et al. 1995; Zattara-
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Hartmann, Badier et al. 1995), measurement of FCSA from vastus lateralis muscle 
biopsies in chronically hypoxemic patients provides a reliable index of muscle fiber 
atrophy.   
Several studies found decreases in FCSA in patients with COPD (Hughes, Katz et al. 
1983; Whittom, Jobin et al. 1998).  Compared to age matched controls, Whittom reported 
a 36% smaller FCSA for type I fibers, an 18% decrease for type IIa, and no difference in 
type IIb. 
Although some report no change in FCSA of human muscle in response to three weeks of 
hypobaric hypoxia (Green, Sutton et al. 1992), muscle fiber atrophy appears to be a 
consistent finding in most studies.  Following up to two months at altitudes greater than 
5,000 m (PIO2 < 78 mmHg), several investigators report a 20-25% decrease in both type I 
and type II muscle FCSA (Green, Sutton et al. 1989; Hoppeler, Kleinert et al. 1990; 
MacDougall, Green et al. 1991; Waynforth and Flecknell 1992). 
Additional studies validate muscle atrophy as well as impaired hypertrophy in response to 
training under hypoxic conditions.  Rats exposed to PIO2 of 57 mmHg for 45 days had a 
decrease in FCSA of both extensor and flexor lower extremity muscles (van Ekeren, 
Sengers et al. 1992).  Narici and Kayser (1995) compared the effects of strength training 
for one month on hypertrophy in humans at sea level versus at 5,050 m (PIO2 ~77 
mmHg); although they used elbow flexors and nuclear magnetic resonance imaging to 
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measure cross sectional area, they found approximately 33% lower values for both 
strength and muscle hypertrophy in the subjects trained at altitude. 
Muscle fiber constituents 
Several muscle fiber constituents are altered during chronic hypoxemia.  Myoglobin 
assists in the flux of O2 into and within the cell.  Metabolic enzymes in the muscle fiber 
serve to catabolize substrates (i.e., glucose and fatty acids) and produce ATP; the fate of 
many intermediary products depends on the presence of O2.  Many of these metabolic 
processes take place within the mitochondria. 
Myoglobin 
Despite its role in the diffusive flux of O2 from the microvasculature to the mitochondria, 
few studies have looked at myoglobin content in either COPD or chronic hypoxia.  The 
one study of patients with COPD and hypoxemia found a decreased myoglobin 
concentration compared to healthy, age matched controls (Moller, Hellstrom et al. 1984).  
However, the soleus muscle of guinea pigs exposed to 5,100 m (PIO2 = 78 mmHg) for 14 
weeks had increased myoglobin content when matched for body mass to normoxic 
animals (Sillau, Aquin et al. 1980). 
Metabolic enzymes 
Several groups have looked at metabolic enzyme activity in the vastus lateralis muscle of 
humans exposed to hypobaric hypoxia (Green, Sutton et al. 1989; Howald, Pette et al. 
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1990; Green, Sutton et al. 1992), with COPD (Jakobsson, Jorfeldt et al. 1995; Maltais, 
Simard et al. 1996; Maltais, LeBlanc et al. 2000), or following lung transplantation 
(Wang, Williams et al. 1999).  Table 2 summarizes these results.  In the hypobaric 
hypoxia studies, the results are the percent change after exposure to ≥ 4,300 m for three 
to six weeks.  The results of the COPD and lung transplantation groups are percent 
change compared to age matched controls.  Of particular interest is the study by Maltais 
et al in 2000, which compared 57 patients with COPD to sedentary controls.    
The consistent finding is that processes taking place in the mitochondria (β oxidation, 
citric acid cycle and oxidative phosphorylation) are either diminished or unchanged.  In 
all cases citrate synthase, the rate limiting step of the citric acid cycle, was reduced by an 
average of ~32%.  Evidence to substantiate an increase in glycolytic activity is less 
conclusive.  However, a decrease in the citrate synthase/phosphofructokinase ratio does 
suggest a shift from aerobic to anaerobic production of ATP, presumably due to cellular 
hypoxia, or insufficient O2 to support oxidative phosphorylation.  It is unfortunate that 
only two of these studies also looked at mitochondrial volume density; however, Howald 
et al (1990) concluded that there was no enzymatic functional impairment, but the 
diminished enzymatic activity was due to the loss of mitochondrial volume.   
Mitochondria 
Rats exposed to PIO2 57 mmHg for almost seven weeks exhibited a decrease in 
subsarcolemmal mitochondrial volume density of both the soleus and extensor digitorum 
longus muscles; however, the intermyofibrillar mitochondrial volume density of the 
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soleus increased (van Ekeren, Sengers et al. 1992).  When mountaineers were exposed to 
≥ 5,300 m (PIO2 ≤ 75 mmHg) for up to two months, both their subsarcolemmal and 
intermyofibrillar mitochondrial volume density had decreased 43 and 13%, respectively, 
a 26% overall decrease (Hoppeler, Kleinert et al. 1990).  A 30% lower mitochondrial 
volume density has also been reported in young permanent high-altitude residents, 4,000 
m (PIO2 = 91 mmHg), compared to age matched lowlanders (Hoppeler and Vogt 2001).  
The only study of mitochondrial content in a patient population, expressed the yield of 
mitochondrial protein as grams of protein per kilogram of muscle mass, reported a 43% 
lower quantity in lung transplant patients when compared to healthy controls (Wang, 
Williams et al. 1999).  
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Table 2.  Muscle enzyme activities. 
 
 
Enzyme Metabolic 
pathway 
Hypobaric 
hypoxia 
COPD Lung 
Tx 
  Green
(1989)
Howald
(1990)
Green
(1992)
Jakobsson
(1995) 
Maltais 
(1996) 
Maltais 
(2000) 
Wang
(1999)
Hexokinase Glycolysis ↓ 53%  ↑ 16%  No ∆  No ∆ 
Phospho-
fructokinase 
(PFK)* 
Glycolysis No ∆ ↑ 9% ↓ 14% ↑ 34% No ∆  ↑ 29%
β-Hydroxyacyl-
CoA-
dehydrogenase 
β oxidation of 
fatty acids 
No ∆ ↓ 27% No ∆ No ∆ ↓ 44% ↓ 24% ↓ 43%
Citrate synthase 
(CS)* 
Citric acid cycle ↓ 37% ↓ 23%  ↓ 29% ↓ 38% ↓ 24% ↓ 45%
Succinate 
dehydrogenase 
Citric acid cycle ↓ 21%  No ∆ No ∆    
Malate 
dehydrogenase 
Citric acid cycle  ↓ 19%      
Cytochrome 
oxidase 
Oxidative phos-
phorylation 
 ↓ 23%      
CS/PFK ratio   ↓ 38%  ↓ 48%   ↓ 58%
Mitochondrial 
content 
   ↓ 26%     ↓ 43%
* indicates rate limiting step  
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Microcirculatory changes 
Due to the importance of the microcirculation to O2 delivery in skeletal muscle and the 
potential for impaired O2 flux in chronic disease, the following is a review of the 
anatomical (capillarity) and physiological (perfusion) changes in the microcirculation 
related to chronic hypoxia.   
Capillarity 
Muscle capillarity is a measure of the quantity of local microcirculation that can be 
measured by several different methods; each of these methods has advantages and 
disadvantages, and may give varying results.  Capillary density (CD, number of 
capillaries per muscle FCSA), capillary-to-fiber ratio (C/F ratio), number of capillaries 
around a fiber, and number of capillary contacts per FCSA are all commonly used 
measures of capillarity, but do not take into account capillary tortuosity or sarcomere 
length, both of which change with muscle contraction (Mathieu-Costello, Ellis et al. 
1991).  Mathieu-Costello (1991) argues that the best measure to assess a muscle’s 
structural capacity for O2 flux is the capillary-to-fiber perimeter ratio, because it takes 
into account the amount of area available for diffusion and does not vary with muscle 
contraction; however, it has not become widely used and none of the subsequent articles 
cited used this measure. 
Only one study looked at capillarity in patients with and without COPD (Whittom, Jobin 
et al. 1998).  Although they saw a reduced number of capillary contacts per fiber, there 
was no difference after correcting for the lower FCSA due to atrophy.  Despite the fact 
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that the 20 patients in the study had a moderately severe obstructive airway disease, they 
were only borderline hypoxemic (PaO2 80 = mmHg), and thus may not have crossed the 
threshold for changes in capillarity.   
The topic of muscle capillarity has been studied by several investigators using either a 
hypobaric chamber (Green, Sutton et al. 1989; MacDougall, Green et al. 1991), or field 
studies of mountaineers in the Himalayas (Hoppeler, Kleinert et al. 1990).  Subjects were 
exposed to altitudes of 5,000 to 8,848 m (PIO2 ~78 – 43 mmHg) for a period of up to 60 
days.  Investigators consistently found an increased CD due to muscle fiber atrophy, and 
an unchanged C/F ratio.  However, permanent high-altitude residents have both a lower 
CD and C/F ratio (Desplanches, Hoppeler et al. 1996). 
Rats have also been used extensively in studies of hypoxia.  Fisher (1992), looking at the 
in vivo rat cremaster muscle after 50 days at ~6,000 m (PIO2 ~68 mmHg), saw not only an 
increased capillary length density, but also increased number of perfused capillaries.  In 
several well-designed studies (Smith and Marshall 1999; Deveci, Marshall et al. 2001), 
Marshall et al compared rats breathing a FIO2 of 0.12 (PIO2 ~86 mmHg) to controls 
breathing room air; they saw a decreased PaO2 (41 vs. 86 mmHg), increased hematocrit 
(50 vs. 43%), decreased body mass, and increased right ventricular mass (due to 
pulmonary hypertension) following only 18 to 21 days of hypoxemia.  Compared to 
control animals, they also reported increased angiogenesis, evidenced by decreased 
interbranch distance between 1°, 2°, and terminal arterioles, and an increased proportion 
of 2° and terminal arterioles, from which O2 flux occurs more easily.  It is unfortunate 
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that these measures of capillarity, “length density,” and “interbranch distance,” cannot be 
compared to other studies.  
Perfusion 
Few studies have looked at the in vivo physiology of blood flow in skeletal muscle during 
chronic hypoxia.  Cassin, in 1971, observed an increased perfusion of capillaries in rats 
exposed to 6,150 m (PIO2 ~67 mmHg) for seven weeks that was not related to an increase 
in capillarity, but rather opening of preexisting vessels (Cassin, Gilbert et al. 1971).  
Nearly 20 years later, Fisher et al (1992), using the cremaster muscle, reported an 
increase in both the anatomic and perfused capillary “length-density” in rats after 7 
weeks at 6,000 m (PIO2 ~68 mmHg).  They also saw an increased RBC flux and capillary 
hematocrit, even when normalized to systemic hematocrit.  In all, they found more 
capillaries, increased perfusion of capillaries, and more RBCs in those capillaries; all 
factors that serve to increase O2 flux into the muscle fiber. 
Summary:  Altered skeletal muscle O2 transport in chronic 
hypoxemia 
Due to the variance in method, intensity, frequency and duration of hypoxia in 
experimental studies and use of different assessment techniques, conclusive evidence 
does not exist regarding the precise effects of chronic hypoxemia on skeletal muscle 
fibers or their associated microcirculation.  Another major problem is clinical relevance:  
most studies look at “short-term chronic hypoxia,” while patients with COPD may be 
hypoxemic for decades, “long-term chronic hypoxia.”  The following is a summary of the 
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overall changes in O2 supply and demand in skeletal muscle in response to both COPD 
and other modes of hypoxemia. 
Supply changes 
Both anatomical and physiological modifications occur locally in the microcirculation 
and muscle fibers, as well as systemically, to increase the convective and diffusive flow of 
O2 from the blood to the mitochondria and help prevent cellular hypoxia.  Since the 
systemic and pulmonary circulations are connected to the heart in series, pulmonary 
hypertension and right heart failure, which can develop due to chronic hypoxemia, impair 
systemic cardiac output and decrease convective O2 delivery ( COQ 2
 ).  In an effort to 
compensate for the hypoxemia, the hormone erythropoietin is upregulated to increase 
[Hb] and thus the quantity of O2 able to be convectively carried in the blood (CaO2).  As 
for systemic effects that increase diffusive O2 delivery, chronic hypoxemia increases 
[2,3-DPG] levels which shifts the O2-Hb curve to the right, facilitating unloading; thus, 
for a lower SO2, there is a higher blood PO2 and a larger driving force (∆PO2) to facilitate 
O2 flux into the cell.  In addition, PCO2 and [H
+] increase with the severity of COPD 
further shifting the Hb-O2 curve to the right.  
It is debatable whether or not chronic hypoxemia promotes angiogenesis locally, or even 
if there is a loss of capillarity.  Following short-term chronic hypoxemia there appears to 
be an increase in CD, while C/F ratio is maintained (Green, Sutton et al. 1989; Hoppeler, 
Kleinert et al. 1990; MacDougall, Green et al. 1991).  This argues against the idea of 
capillary angiogenesis in humans exposed to hypoxia, because the increased CD is due to 
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a decrease in muscle FCSA (Hoppeler and Vogt 2001).  With or without angiogenesis, an 
increased CD would mean a greater supply of O2 to the muscle per unit of contractile 
mass due to increased capillary surface area per fiber area and decreased diffusion 
distances associated with smaller fiber diameters.  However, the Desplanches et al (1996) 
study of permanent high-altitude residents reported that CD and C/F ratio were both 
reduced in proportion to the loss of mitochondria and oxidative potential, suggesting that 
O2 supply does decline over time. 
Regardless of the number of capillaries per muscle fiber, these capillaries must be 
perfused in order to participate in the diffusive flux of O2 into the muscle fiber.  Although 
few studies have looked at the in vivo perfusion of skeletal muscle following short-term 
chronic hypoxia, those that have suggest an increase in the number of perfused capillaries 
(Cassin, Gilbert et al. 1971; Fisher, Schrader et al. 1992).  As mentioned above, this 
would enhance O2 flux by increasing surface area and decreasing diffusion distance.  
Also, the increased RBC supply rate and capillary hematocrit reported by Fisher et al 
(1992) would potentially serve to increase convective O2 delivery, raising blood PO2, 
thereby increasing the driving force for O2 diffusion into the muscle. 
Another factor that would enhance O2 flux into the muscle fiber is an increase in muscle 
myoglobin.  While short-term hypoxia (14 days) increased [Mb] (Sillau, Aquin et al. 
1980), hypoxemic patients with COPD had decreased [Mb] concentrations (Moller, 
Hellstrom et al. 1984).  Although traditionally regarded as consumers of O2, muscle 
fibers can also improve the influx of O2 by the position of their mitochondria.  
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Subsarcolemmal mitochondria decrease the diffusion distance for O2 when compared to 
intermyofibrillar mitochondria.  However, several studies report that there is a loss of 
subsarcolemmal mitochondria (Hoppeler, Kleinert et al. 1990; van Ekeren, Sengers et al. 
1992), which would also decrease the diffusion conductance of O2 by increasing 
diffusion distance. 
Demand changes 
In the mitochondria, the enzyme cytochrome oxidase contains the final binding site for 
O2 before it is reduced to H2O.  Despite it’s importance, only one study (Howald, Pette et 
al. 1990) has looked at cytochrome oxidase activity in short-term chronic hypoxia; they 
found that it had decreased 23% in mountaineers following six weeks of exposure to a 
PIO2 of ≤ 75 mmHg.  Not surprisingly, this reduction was in close proportion to the 26% 
decrease in mitochondrial volume density that they reported, and similar to the 30% 
reduction seen in long-term chronic hypoxia (Hoppeler and Vogt 2001). 
Muscle fiber type is relevant to the topic of O2 demand because different fiber types 
derive their supply of ATP preferentially from different sources, type I from oxidative 
phosphorylation and type IIb from glycolysis.  Type I fibers not only require more O2 
than type II for ATP synthesis, but since they contract more often (they are the first to be 
activated and the last to fatigue), they consume more ATP and demand more O2.  Thus, it 
is not surprising that hypoxemic patients with COPD and permanent high-altitude 
residents demonstrated a muscle fiber type transformation from I to II, as this would 
decrease O2 demand. 
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The consistent finding of muscle atrophy in nearly all studies of chronic hypoxia is also 
significant in regard to O2 demand.  Smaller cells contain fewer enzymes and contractile 
proteins that must be synthesized and maintained at the expense of ATP and O2; thus, 
fiber atrophy could be an adaptive response to diminished resources.  
Conclusion 
Taken as a whole, there seem to be significant differences in the effects of short-term 
versus long-term chronic hypoxemia; however, the effects of both are attempts to 
maintain homeostasis.  Although the time sequence of the changes is not known, it 
appears that short-term hypoxemia results in changes that increase O2 supply to skeletal 
muscle.  Despite these efforts to maintain normal tissue oxygenation, tissue PO2 remains 
low and the muscle fibers undergo adaptive strategies in the first few months of 
hypoxemia to decrease O2 demand:  decreased fiber size, muscle fiber type 
transformation, and decreased oxidative capacity (loss of mitochondria and aerobic 
enzymes).  Over the long-term, however, this decreased O2 demand leads to a decreased 
O2 supply to the muscle, but the mechanism by which this occurs remains to be 
discovered.   
Therefore, the long-term changes seen in muscle fibers and their associated 
microcirculation in response to chronic hypoxemia could be intended to decrease O2 
conductance (supply and demand) in skeletal muscle in order to preserve blood PO2 for 
more vital organs.  This could explain why there is a persistent exercise limitation 
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following lung transplantation, where the hypoxemia is cured, but its long-term effects 
are not.   
Animal model of COPD 
The development of animal models of COPD, in particular emphysema, began in the mid-
1960’s with Eriksson’s discovery of α 1-antitrypsin deficiency (Laurell and Eriksson 
1963; Eriksson 1965), and simultaneous with Gross’ finding of enzymatically produced 
pulmonary emphysema (Gross, Babjak et al. 1964; Gross, Pfitzer et al. 1965).  Since 
1973, porcine pancreatic elastase has been the primary enzyme used to reliably reproduce 
emphysema in animals (Kaplan, Kuhn et al. 1973; Lucey, Keane et al. 2002).  Initially, 
studies in hamsters focused on model and technique development of elastase-induced 
emphysema (Kaplan, Kuhn et al. 1973), as well as documenting pulmonary histological, 
stereological, and physiological changes that occur following elastase instillation (Kuhn 
and Tavassoli 1976; Kuhn, Yu et al. 1976; Snider and Sherter 1977; Snider, Sherter et al. 
1977).  More recently, intratracheal elastase instillation has been validated as an 
experimental model of emphysema in rats (Damon, Mauderly et al. 1982; Busch, 
Buschbom et al. 1984; Busch, Lauhala et al. 1984; Sato, Kato et al. 1990; Finlay, 
O'Donnell et al. 1996). 
Animals treated with a single intratracheal instillation of porcine pancreatic elastase 
exhibit the same characteristics as humans with emphysema (Snider, Lucey et al. 1986): 
altered pulmonary function tests (increased residual volume, functional residual capacity, 
and total lung capacity) (Snider and Sherter 1977; Snider, Sherter et al. 1977; Damon, 
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Mauderly et al. 1982), impaired gas exchange (decreased diffusion capacity and arterial 
blood oxygen levels) (O'Brien, Lucey et al. 1979; Lucey, O'Brien et al. 1980; Damon, 
Mauderly et al. 1982; Sexton and Poole 1998), and cardiovascular sequelae (pulmonary 
hypertension and right ventricular hypertrophy) (Icochea, Cooper et al. 1982; Sato, Kato 
et al. 1994). 
While the morphogenesis of emphysema begins within hours of the elastase instillation  
(Kuhn, Yu et al. 1976; Busch, Lauhala et al. 1984), the structural changes in the lung are 
relatively stable after six weeks (Snider and Sherter 1977).  However, it is not known 
how muscle morphology may change over time, or how oxygenation, blood flow, and 
muscle function may be altered in animals with “stable” emphysema and chronic 
hypoxemia.  
To my knowledge, there are only two published investigations into the effects of chronic 
emphysema on peripheral skeletal muscle.  Mattson and Poole reported similar activity 
levels between control and emphysematous hamsters (7 to 8 months old), but citrate 
synthase levels in the vastus lateralis and gastrocnemius muscles were 7%  and 13% 
lower in the emphysematous hamsters (Mattson and Poole 1998).  By contrast, in a 
different study they reported no difference in hindlimb blood flow, using 15 µm-diameter 
radiolabeled microspheres, but did find that blood flow to respiratory muscles in 
emphysematous hamsters was higher during exercise than in controls (Sexton and Poole 
1998).  This group also found that microvascular PO2 in the diaphragm was ~35% lower 
in emphysematous versus control hamsters.   
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Spinotrapezius muscle  
Gray originally described the spinotrapezius muscle preparation in 1973 as “an ideal 
preparation for the microscopic study of a skeletal muscle vascular bed;”  it is easily 
accessible, thin enough for trans-illumination, and its neurovascular supply can remain 
intact (Gray 1973).  The spinotrapezius’ parallel muscle fibers originate from the spinous 
processes of the 4th thoracic through the 3rd lumbar vertebrae, as well as a small segment 
of the thoracolumbar fascia, and inserts onto the spine of the scapula.  The muscle has 
dual innervation from both cranial and peripheral nerves (spinal accessory (cranial nerve 
XI), and 2nd and 3rd cervical nerves, respectively) (Gray 1973).  Its main blood supply, 
from the large spinotrapezius feeding artery (via subscapular branch of axillary artery), 
enters near the scapula; a few other feeding arteries/arterioles enter the muscle either near 
the caudal or cephalad border of the muscle (Schmid-Schonbein, Firestone et al. 1986) 
(refer to Figure 3). 
Since Gray’s original article, nearly 40 articles have been published using the 
spinotrapezius muscle, either describing its anatomy (Engelson, Schmid-Schonbein et al. 
1985; Engelson, Skalak et al. 1985; Engelson, Schmid-Schonbein et al. 1986; Schmid-
Schonbein, Firestone et al. 1986; Skalak and Schmid-Schonbein 1986; Saltzman, DeLano 
et al. 1992), characterizing its contractile properties and fiber type (Taylor and Calvey 
1977; Delp and Duan 1996), describing its normal microvascular physiology (Lash and 
Bohlen 1987; Lash 1994; Suzuki, Poole et al. 1995; Musch and Poole 1996; Poole, 
Musch et al. 1997; Kindig and Poole 1998; Lash 1998; Lash 1998; Kindig and Poole 
1999; Richmond, Shonat et al. 1999; Bailey, Kindig et al. 2000; Behnke, Kindig et al. 
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2001; Bishop, Nance et al. 2001; Kindig and Poole 2001; McDonough, Behnke et al. 
2001; Behnke, Kindig et al. 2002; Bishop, Popel et al. 2002; Kindig, Richardson et al. 
2002; Smith, Golub et al. 2002; Kano, Padilla et al. 2004) as well as functional and 
microcirculatory changes associated with hypertension (Schmid-Schonbein, Firestone et 
al. 1986; Lash and Bohlen 1995; Smith, Barbee et al. 2004; Smith, Barbee et al. 2004), 
skeletal muscle ischemia (Suzuki, Poole et al. 1995), diabetes (Kindig, Sexton et al. 
1998), chronic heart failure (Kindig, Musch et al. 1999; Richardson, Kindig et al. 2003; 
Behnke, Delp et al. 2004), and aging (Russell, Kindig et al. 2003).  The fact that surgical 
exteriorization of the spinotrapezius does not alter microvascular PO2 and blood flow 
when compared to the intact state (Bailey, Kindig et al. 2000) makes it an ideal tissue to 
measure oxygen transport and consumption.  Surprisingly, no one has used the 
spinotrapezius muscle, or any other peripheral skeletal muscle, to investigate 
microvascular oxygen transport or muscle contractile changes related to chronic 
hypoxemia or COPD. 
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Figure 3. Microvascular network of rat spinotrapezius muscle (Engelson, Skalak et 
al. 1985). 
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Purpose of present study 
The overall purpose of this series of investigations was to test the hypothesis that the 
principle of symmorphosis, regulated morphology “commensurate to functional needs” 
(Weibel 1984; 2000), is operative under conditions of chronic hypoxia.  If it is, then one 
might expect that 1) chronic systemic hypoxemia leads to diminished oxygen demand 
from the muscle due to slow-to-fast fiber type transformations and reduced oxidative 
enzyme capacity, and 2) that this chronic reduction in tissue oxygen demand would 
remove the stimulus for angiogenesis (i.e., vascular endothelial growth factor) and lead to 
vascular rarefaction, further diminishing oxygen supply, as has been seen in other chronic 
disease models (hypertension and heart failure) (Hansen-Smith, Greene et al. 1990; Nusz, 
White et al. 2003).  This proposed negative-feedback loop is illustrated in Figure 4. 
There is no animal model of “skeletal muscle dysfunction in COPD,” but there is 1) an 
excellent animal model of emphysema, and 2) an ideal skeletal muscle for studying the 
microcirculation.  Thus, the objectives of my study, in relation to the above hypothesis, 
were to:   
1. validate elastase-induced emphysema in rats as an animal model of skeletal 
muscle dysfunction in COPD,  
2. determine if there is a relationship during aging between severity of hypoxemia 
and transformations in muscle fiber type,  
3. investigate differences in oxygen transport and skeletal muscle function in the 
spinotrapezius muscle of animals with and without COPD, and  
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4. determine if short-term supplemental oxygen improves oxygen supply and muscle 
performance of the spinotrapezius.   
The independent measures included both local skeletal muscle O2 supply and demand 
parameters, and muscle performance, as well as systemic measures of O2 supply and 
evaluation of respiratory function. 
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Figure 4. Proposed negative-feedback loop.  As tissue O2 delivery becomes impaired, 
so does muscle fiber O2 supply, and consequently O2 demand; likewise, as fiber O2 
demand decreases during chronic hypoxia, this may lead to a decrease in O2 supply. 
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Materials, Methods, and Data Analysis 
 
Based on the objectives of this study, there were two phases of this project: 
I. validation of elastase-induced emphysema as an animal model of skeletal muscle 
dysfunction in COPD (i.e., transformation of muscle fiber type with aging and 
hypoxemia) and  
II. investigation of oxygen consumption and skeletal muscle performance differences 
in animals with and without COPD, and the effects of supplemental oxygen on 
these parameters.   
Each phase was preceded by the initial intervention:  endotracheal instillation of either 
elastase or saline.  Many of the materials and methods were used in both phases of the 
study; others were unique to one phase or the other.  For convenience of reference, the 
various experimental methods and techniques are described first, followed by the details 
of each protocol.  Further details of some aspects are found in the appendices.  This study 
was approved in advance by Virginia Commonwealth University’s Institutional Animal 
Care and Use Committee (protocol # 0206-3081), and all animals were treated in 
accordance with the Institute for Laboratory Animal Research’s Guide for the Care and 
Use of Laboratory Animals (1996). 
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Experimental Animals 
Seventy-six Sprague-Dawley rats (Harlan, Indianapolis, IN) with a mean initial body 
mass of 215.5 g (SD 14.5, range 176 – 248) were used in these experiments.  Since the 
spinotrapezius muscle of male rats is thicker and contains more connective tissue, giving 
poorer image quality for intravital microscopy, female rats, which have a lower maximal 
body mass (Figure 5), were used.  Animals were housed in individual cages and 
maintained on a 12:12 hr light-dark cycle in a climate-controlled room (temperature 68-
75° F, humidity 40-60%), with access to rodent chow and water ad libitum.  Animals 
were delivered to the institutional animal care facility at 8.3 (SD 0.6) weeks of age, and 
were given two weeks for acclimatization.  At a mean age of 10.6 (SD 0.7) weeks of age 
(range 9.6 – 12.0), the initial intervention (intratracheal instillation, described in “Initial 
intervention:  Elastase/vehicle instillation,” page 41) was performed.  The terminal 
experiments were completed between 4 and 65 weeks after the initial intervention.  
Following a purported outbreak of Rat respiratory virus, the 16 animals used in phase II 
were housed in filter-top cages.  
The influence of hypothermia, dehydration, infection, and pain were all addressed.  To 
prevent hypothermia, all animals were kept at ~37° C, verified by rectal thermometer 
(Model 2018, Lumiscope, East Brunswick, NJ), using a homeothermic blanket system 
(Harvard Apparatus, Holliston, MA) and/or a thermostatic animal platform (Appendix I) 
(Golub and Pittman 2003).  Due to the short duration of phase I experiments, dehydration 
was not an issue; during phase II experiments dehydration was prevented by intravenous 
administration of fluorescent and phosphorescent probes dissolved in phosphate buffered 
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saline (PBS), as well as a continuously infused anesthetic (Saffan, ~0.3 ml/hr).  A 
prophylactic antibiotic, 60 mg tetracycline/L drinking water (Polyotic, Fort Dodge 
Animal Health, Fort Dodge, IA, Lot # 010805) was administered for seven days after the 
initial intervention to prevent mortality from suppurative pneumonia (Busch, Lauhala et 
al. 1984).  To assess and prevent undue distress, discomfort, or pain, animals were 
monitored daily for one week after the intratracheal instillation, and scored using the 
“Modified distress scoring sheet” (Lloyd and Wolfensohn 1999) (Appendix II) a 
predictor of animal mortality; it was not necessary to euthanize any animal due to 
distress.   
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Figure 5. Sprague-Dawley male vs. female growth curve. 
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 Anesthesia 
Induction of anesthesia for the initial intervention and phase I experiments was 
accomplished by placing animals in an induction chamber (Anesthetizing box, Harvard 
Apparatus) with 4% Isoflurane (AErrane, Lot # N009B310, Baxter, Deerfield, IL) and 
96% oxygen, administered with a gas vaporizer (Quantiflex VMC Small Animal 
Anesthesia Machine and VIP 3000 Veterinary Anesthesia Vaporizor, MDS Matrx, 
Orchard Park, NY).  The animals were then orally intubated and placed on a small-animal 
pressure controlled ventilator (RSP1002, Kent Scientific Corp., Litchfield, CT), receiving 
maintenance anesthesia of 2% Isoflurane (Waynforth and Flecknell 1992) and 98% 
oxygen.   
For the terminal microcirculatory experiments (phase II), animals were initially 
anesthetized with a combination of Ketamine (75 mg/kg) and Acepromazine (2.5 mg/kg) 
(Waynforth and Flecknell 1992).  Maintenance of anesthesia throughout the experiment 
was accomplished using intravenous (i.v.) Saffan (Alphaxolone 9 mg/ml and 
Alphadolone 3 mg/ml, Schering-Plough Animal Health, Hertfordshire, England, Lot 
20081) at an initial rate of 0.3 ml/hr (~0.2 mg/kg/min) (Waynforth and Flecknell 1992), 
which was titrated to maintain a mean arterial pressure of 95-105 mmHg. 
Following the terminal experiments, animals were euthanized by administering Euthasol 
(Pentobarbital 390 mg/ml and Phenytoin 50 mg/ml, Delmarva Laboratories, Inc., 
Midlothian, VA) at a dose of 0.4 ml/kg (~150 mg/kg) (Goldberg and Henry 2000).   
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Tracheal and vascular cannulations 
A set of vascular and tracheal cannulae were made from various sizes of polyethylene 
(PE) tubing (Figure 6).  Endotracheal tubes (ETT) were made from PE 190 tubing, 6.5 
cm long, with a teardrop shaped bulb placed ~2 cm from one end to seal the airway at the 
vocal cords, as described by Smith et al (2004).  A tracheostomy tube was made from a 5 
cm section of PE 240 tubing.   
Both the initial intervention and phase I required oral endotracheal intubation.  Following 
induction anesthesia, the vocal cords were visualized using a laryngoscope with a 
modified Miller # 0 fiber optic blade (Welch Allyn, Skaneateles Falls, NY), while the 
ETT with stylet was inserted into the trachea between the vocal cords during inspiration 
(Costa, Lehmann et al. 1986; Smith, Tiba et al. 2004).  The laryngoscope and stylet were 
removed, the animal placed on mechanical ventilation, and correct ETT placement 
verified by observing the chest rise and fall in synchrony with the ventilator.  A 
tracheostomy tube was placed during phase II experiments to maintain a patent airway, 
decrease work of breathing, and allow port of entry for inspiratory gases.   
The right femoral artery was cannulated for arterial blood gas (ABG) samples during 
phase I experiments (Waynforth and Flecknell 1992).  In phase II experiments, the right 
external jugular vein and left common carotid artery were cannulated and used for 
measurements of central venous pressure (CVP) and systemic arterial pressure (AP), 
respectively.  The measurements were collected at 100 Hz using pressure transducers 
connected to a high-speed data acquisition system (MP150, BIOPAC Systems, Inc., 
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Goleta, CA) via a RJ-11 cable, transducer connector interface (TCI-105, BIOPAC), and 
general purpose transducer amplifier (DA100C, Biopac).  This acquisition system was 
connected to a personal computer (PC) equipped with a digital chart recorder 
(AcqKnowledge software, v3.7.3, BIOPAC).  In addition, the jugular venous line was 
used for continuous infusion of i.v. Saffan, and the carotid arterial line was used for ABG 
sampling.  The right femoral vein was also cannulated during phase II experiments for 
i.v. injections of various experimental solutions.  Patency of vascular cannulae was 
maintained with either a heparin lock (20 units of heparin/ml of normal saline) or 
continuous infusion. 
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Figure 6. Vascular and tracheal cannulae (A.  Femoral arterial (PE 50-20-10), B. 
Carotid artery (PE 90-50), C. Femoral venous (PE 50), D. External jugular venous 
(PE 90), E. Endotracheal (PE 190 with "bulb"), and F. Tracheostomy (PE 240)). 
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Initial intervention:  Elastase/vehicle instillation 
Lyophilized porcine pancreatic elastase (Elastin Products Company, Inc., Owensville, 
Missouri, EC134, 135 units of activity/mg of protein, Lot 52669) was dissolved in normal 
saline to give a concentration of 400 international units/ml of saline, and was 
administered at a dose of 80 units/100 g body mass (0.2 ml/100 g).  Animals in the 
vehicle control group received an equivalent volume of normal saline (0.2 ml/100 g)  
Following placement of an ETT, the animals remained hanging on the intubation board 
and were allowed to rest for three minutes on the ventilator.  At that point, they were 
positioned on their left side at 60°, were temporarily removed from the ventilator, and 
half of their total dose was instilled into the ETT via a 1-ml syringe equipped with a 
sterile 20-gauge needle (Busch, Lauhala et al. 1984; Sato, Kato et al. 1990).  The animals 
were placed back on the ventilator for two minutes in order to 1) maintain anesthesia, 2) 
ensure adequate ventilation and oxygenation, and 3) to assist in the distribution of the 
elastase.  Following rotation to the right, and instillation of the remaining dose of 
elastase/vehicle, they were, again, placed on the ventilator for two minutes.  At this point 
they were taken off the ventilator, and thus anesthesia.  The ETT was removed as the 
animal awakened, and it was returned to its housing following a resumption of normal 
activity and no signs of respiratory distress, as determined by a score of ≥ 12/19 on the 
“Modified distress scoring sheet” (Lloyd and Wolfensohn 1999) for three hours.  
Prophylactic antibiotics (60 mg tetracycline/L drinking water; Polyotic, Fort Dodge 
Animal Health) were administered for seven days to prevent mortality from suppurative 
pneumonia (Busch, Lauhala et al. 1984).   
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Radiography 
Ventral-dorsal (VD) and lateral chest radiographs were made of two animals, one 
experimental and one control, in the Department of Animal Resources with the assistance 
of a veterinary technologist and a veterinarian.  These radiographs were made, 
approximately 19 weeks after the initial intervention, on living animals while intubated 
and anesthetized with Isoflurane, as previously described (“Anesthesia,” page 39), during 
a “sigh” breath from the ventilator (with a maximal inspiratory pressure of 10 cmH2O).  
Radiographs were taken using a Universal MP 300 X-ray unit used at a 40-inch distance 
set at 2 milliamp-seconds as well as 50 and 48-kV peak, respectively, for VD and lateral 
radiographs, resulting in an exposure time of 0.006 sec (Snider and Sherter 1977). 
MHC isoform determination 
The relative proportions of myosin heavy chain isoforms I, IIa, IIx/d, and IIb from each 
muscle were determined using the sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) technique of Talamadge and Roy (1993), as modified by 
Kinirons (2002). 
Muscle biopsy and tissue processing 
After being euthanized, the left vastus lateralis, gastrocnemius, soleus, and spinotrapezius 
muscles were isolated and removed from the animals by open biopsy, weighed, placed in 
a microcentrifuge tube, quickly frozen in liquid nitrogen and stored at -70° C.  The frozen 
muscles were later lyophilized, minced with scissors, homogenized with a mortar and 
pestle, and placed in a cold extraction buffer (see Appendix IV, MHC extract solution) 
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(Zhang, Wright et al. 1997).  Following agitation every ten minutes, at 4° C for 60 
minutes, the samples were centrifuged at 10,000 G for 10 minutes.  A small portion of the 
supernatant, containing extracted MHC, was pipetted into microcentrifuge tubes and 
stored at -70° C. 
At a later time, the extracted muscle samples were brought to room temperature, mixed in 
a vortex mixer, and the protein concentration assayed, based on the method of Bradford 
(1976) using a microplate absorbance reader at a wavelength of 595 nm (Tecan Sunrise, 
Phenix Research Products, Hayward, CA) calibrated with known concentrations of 
bovine serum albumin (Figure 7).  If necessary, samples were diluted with additional 
extract solution to achieve a protein concentration of ~0.25 mg/ml and stored at -70° C.   
On the day in which the SDS-PAGE was run, the diluted muscle samples were again 
brought to room temperature, mixed in a vortex mixer, and combined with an equal 
volume of sample buffer (see Appendix IV), yielding a final protein concentration of 
~0.125 mg/ml.  This sample was boiled for five minutes to help denature the protein, and 
then cooled to room temperature prior to loading into the gel. 
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Figure 7. Protein assay calibration curve. 
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SDS-PAGE 
The SDS-PAGE procedure, briefly described below, is detailed in the PROTEAN II xi 
Cell Instruction Manual, section 4.1:  “Casting Discontinuous (Laemmli) Gels” (Bio-Rad 
Laboratories, Hercules, CA). 
The 8% SDS separating gel solution (see Appendix IV), immediately after addition of the 
polymerizing agents, was injected between two glass plates in a casting stand to a height 
of ~13 cm.  This 0.75 mm thick gel was layered with ~1 cm 10% ethanol, and allowed to 
set for at least 45 minutes.  At this point, the ethanol was poured off, and Whatman #1 
filter paper was used to dry between the glass plates.  A 15-space comb was inserted 
between each plate prior to injecting the 4% SDS stacking gel solution (Appendix IV) to 
form the “wells” into which the muscle samples were injected.  The stacking gel was 
allowed to set for at least 60 minutes; the comb was gently removed, and each well was 
individually and gently cleaned by an injection of the upper running buffer from a 5-ml 
syringe and 23-gauge needle. 
Twenty µl of each sample were slowly injected into a separate well, yielding ~2.5 µg of 
protein per lane.  The first and last wells were not used, and a standard (Precision Plus 
Protein Standard, 161-0374, Bio-Rad) was placed in the middle to help identify the bands 
of interest.  The glass plate sandwich was then locked into a cooling core, and the upper 
and lower buffer chambers were filled with their respective buffer solutions (see 
Appendix IV), respectively.  The central cooling core was placed in the lower buffer 
chamber, and 400 µl of 2 β-mercaptoethanol were added to the upper buffer chamber. 
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The lower buffer chamber, with the lid in place, was placed in the refrigerator, leveled, 
and the electrodes plugged into the electrophoretic system power supply (Power Pac 
1000, Bio-Rad).  The electrophoresis unit ran at a constant voltage of 275 volts for ~30 
hours (maximal current of 20 mA per gel for 90 minutes, followed by a maximum of 15 
mA per gel for the remaining time). 
Gel staining and analysis 
Immediately after removal from the glass plates, each gel was placed in a fixative 
solution (Appendix IV) for 20 minutes, rinsed twice with deionized water for 10 minutes, 
and stained with silver (Silver Stain Plus Kit, 161-04149, Bio-Rad).  After adequate 
staining, the gels were placed in a stop solution (5% acetic acid) for 15 minutes, and 
rinsed for again for five minutes.  In each of the above steps, the gels were gently agitated 
on a platform shaker (Innova 2000, New Brunswick Scientific Co., Inc., Edison, NJ). 
Gels were removed from the rinse solution and immediately scanned with a high-
resolution scanner (Duoscan HiD, AGFA, Belgium).  These images were saved onto a PC 
and later analyzed offline with Gel-Pro Analyzer, MediaCybernetics, Silver Spring, MD), 
which was used to determine the relative fraction of total MHC isoform expression.  
Since each band, containing a different MHC isoform, was evaluated relative to other 
bands in the same lane (muscle), differences in protein concentrations and staining 
intensity between different lanes was not an issue.  In addition, to make staining more 
uniform, only one type of muscle was analyzed on a single gel, and the protein content 
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per lane was uniform.  Determination of MHC type from the stained gels was based on 
the migration order, I > IIb, IIx, > IIa (Figure 8) (Talmadge and Roy 1993). 
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Figure 8. MHC bands after SDS-PAGE and silver staining.  MHC I has the greatest 
electrophoretic mobility, followed by IIb, IIx and then IIa, with the least. 
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Spinotrapezius muscle preparation 
The spinotrapezius muscle was prepared as previously described (Gray 1973; Lash and 
Bohlen 1987; Suzuki, Poole et al. 1995).  After exposing the muscle through a dorsal, 
midline incision, the layer of subcutaneous fat and connective tissue was gently removed, 
while taking care not to damage the underlying muscle.  Bleeding was prevented or 
controlled by using a cautery, and the tissue was keep moist with frequent applications of 
normal saline.  Muscle length was measured on the lateral border of the spinotrapezius 
muscle, from the origin on the thoracolumbar fascia to its insertion on the spine of the 
scapula.   
After the entire lateral border of the spinotrapezius muscle was gently separated from the 
underlying latissimus dorsi muscle, and the penetrating vessels at the caudal end were 
cauterized, an 8 cm, 28-gauge wire (~60 mg), in the shape of a horseshoe (Suzuki, Poole 
et al. 1995), was sutured to the lateral border at 8-10 mm intervals using 5-0 silk sutures.  
This “horseshoe” was then sutured to the muscle at 8-10 mm intervals as it was cut from 
its caudal, and then medial origins; in this process, a medial feed arteriole was cauterized 
as well.  The wire horseshoe served as a rigid interface to attach the muscle to the force 
transducer (Figure 9), and also kept the muscle flat, near its in situ position, on the 
platform before and after muscle contractions.   
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Figure 9. Spinotrapezius muscle on pedestal connected to force transducer and 
covered by Saran film. 
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Intravital microscope 
During the data collection phase of the experiment, both transmission and episcopic 
illumination images of the spinotrapezius preparation were continuously recorded from 
an upright Zeiss ACM microscope (Carl Zeiss, Inc., Göttingen, Germany).  
Transillumination and epifluorescent images were continuously recorded onto a video 
cassette recorder (VCR; Panasonic AG 7350) using a charge-coupled device camera 
(CCD-72, Dage MTI, Michigan City, IN); these images were visualized on a 20” video 
monitor (Panasonic WV 5490).  The light source for both fluorescence and 
phosphorescence excitation was a Xenon flash lamp (Model FX-249, EG&G 
Optoelectronics, Salem, MA), with an output of 0.5 J, duration of 3 µs, used at a 
frequency of 100 Hz and 20 Hz, respectively.  
For epifluorescence microscopy, used for blood velocity measures, a fluorescence filter 
cube was used (Figure 10) (11001v2, Chroma Technology Corp., Rockingham, VT) with 
an 1) excitation filter with a center wavelength at 470 nm and full bandwidth of 40 nm, 2) 
dichroic, longpass beamsplitter with a cut-on wavelength of 495 nm, and 3) longpass 
emission filter with a cut-on wavelength of 515 nm (Figure 11). 
For phosphorescence microscopy, used for microvascular PO2 measures, a filter cube was 
used with a 1) 430 nm bandpass excitation filter (430BP100, Omega Optical Inc., 
Brattleboro, VT), 2) dichroic, longpass beamsplitter with a cut-on wavelength of 510 nm 
(FT510, Zeiss), and 3) an emission filter with a cut-on wavelength of 650 nm (Oriel 
Corp., Stratford, CT).   
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Figure 10. Flourescence filter cube (Chroma 11001v2). 
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Figure 11. Chroma flouresence filter cube's (11001v2) excitation filter, dichroic 
mirror, and emission filter characteristics. 
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Phosphorescence quenching microscopy 
Hardware 
The microscope, excitation source and filter set were described above.  Following 
excitation at 10 Hz through a 32 µm square diaphragm, the emitted phosphorescence 
signal from the spinotrapezius muscle was sent to a photomultiplier tube (model R1617, 
Hamamatsu, Middlesex, NJ).  Output from the photomultiplier was sent to a low-noise 
current-to-voltage converter (model OP27EP, Analog Devices, Norwood, MA).  That 
signal was sent to both an analog-to-digital converter (AT MIO/6F5, National 
Instruments, Austin, TX) in a PC, and it was monitored on an oscilloscope (model 72-
3060, Tenma Test Equipment, Springboro, OH) to ensure that the signal was 
approximately 8 volts (near the maximal input voltage of 10 V for the analog-to-digital 
converter); this setup is diagramed in Figure 12 (Zheng, Golub et al. 1996). 
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Figure 12. Schematic diagram of phosphorescence quenching microscopy setup. 
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Palladium-porphyrin phosphorescence probe preparation 
Preparation of the albumin-bound Palladium-porphyrin phosphorescence probe (10 
mg/ml) was a multi-step process, whose details are included in Appendix III.  In brief, it 
included preparing a solution of bovine serum albumin, fraction V (Sigma-Aldrich, Inc., 
St. Louis, MO), to which palladium meso-tetra (4-carboxylphenyl) porphyrin (Pd-
MTCPP; Oxygen Enterprises, Ltd., Philadelphia, PA) was bound.  This solution was 
dialyzed in polyvinylpyrrolidine (Sigma-Aldrich, Inc.) for ~24 hours to remove any 
unbound Pd-MTCPP from the solution.  The pH was adjusted to 7.3 – 7.5 with the 
addition of Trizma base (Sigma-Aldrich, Inc.).  The final product was filtered using a 
sterilization filter unit (NALGENE Labware, Rochester, NY), pipetted into 0.5 ml 
microcentrifuge tubes, immediately frozen in liquid nitrogen, and stored at -80° C. 
Data acquisition and microvascular PO2 analysis 
LabVIEW 4.01 (National Instruments) was used to acquire and process the signal from 
the analog-to-digital converter at a sampling rate of 100 kHz.  Twenty decay curves per 
measurement, 400 points per decay curve, were normalized, averaged, and saved in 
LabVIEW for off-line analysis. 
Measuring PO2 using the phosphorescence quenching method is based on the relationship 
between phosphorescence lifetime, τ, and PO2, using the Stern-Volmer equation: 
Equation 4 
20/1/1 OqPk+= ττ  
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where τ0 is the lifetime in the absence of oxygen (546 µs), and kq is the quenching 
coefficient (3.06·10-4 µs-1·mmHg-1).  Normalized, averaged phosphorescence decay 
curves were analyzed using Origin 7.05 (OriginLab).  Each curve was plotted on a semi-
logarithmic scale, and analyzed using a non-linear curve fitting equation, based on the 
rectangular (R) distribution model of oxygen as developed by Golub et al (1997): 
Equation 5 
)/exp()1()()( FR tAtYAtY τ−−+⋅=  
where A is the fraction of the observed signal due to phosphorescence, (1-A) is the 
fraction contributed by the tail of the excitation flash, τF is the lifetime of the residual 
flash contribution, t is time in µs, and )(tYR  Equation 6 is the relationship between 
phosphorescence decay rate and PO2 (k0 is 1/τ0, and δ is the half-width of the rectangular 
distribution) (Golub, Popel et al. 1997). 
Equation 6 
( ) ( )[ ] ( ) tktktPkktY qqOqR δδ /sinhexp 20 +−=  
A representative plot, Figure 13, illustrates this relationship. 
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Figure 13. Representative phosphorescence decay curve. 
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Spinotrapezius oxygen consumption 
Oxygen consumption of the spinotrapezius muscle was calculated based on Fick’s 
principle, using spinotrapezius blood flow STQ , and the arteriolar-venular oxygen content 
difference (CaO2-CvO2) as described in Equation 7: 
Equation 7 
( )222 OOSTSTO CvCaQV −=  , 
where CO2 is the oxygen content of blood (ml of O2/dl of blood), and the subscripts “a” 
and “v” refer to arteriolar and venular blood, respectively.  Measurement of blood flow is 
discussed in the following section “Blood flow.” 
Oxygen content 
CO2 includes oxygen both bound to hemoglobin and dissolved in blood, as defined in 
Equation 8:  
Equation 8 
222 ][2 OOHbOO PCHbSC ⋅+= α , 
where SO2 is the fractional oxygen saturation of hemoglobin, [Hb] is hemoglobin 
concentration (g/dl), CHb is the oxygen binding capacity of hemoglobin (1.39 ml of O2/g 
of Hb), 2Oα is the solubility coefficient of oxygen in whole blood (0.003 ml of 
O2/dl·mmHg), and Po2 is the partial pressure of oxygen (mmHg), which was determined 
using phosphorescence quenching microscopy.   
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Hemoglobin concentration, [Hb], was calculated from Equation 9: 
Equation 9 
[ ])(][ MetHbCOHbtHbtHbHb +⋅−=  
where tHB is total hemoglobin concentration, COHb and MetHb are the fraction of tHb 
that is either carboxyhemoglobin or methemoglobin, respectively.  It was assumed that 
spinotrapezius arteriolar and venular [Hb] were equivalent to carotid artery [Hb].  This 
end result is the quantity of hemoglobin available for binding to oxygen. 
SO2 was calculated from microvascular Po2, based on the rat oxyhemoglobin dissociation 
curve ( 
Figure 1, page 7) using the Hill model and Mathcad 2000 (MathSoft, Inc., Cambridge, 
MA): 
Equation 10 
( )
( )nvirtualO
nvirtual
O
OO
PP
PSS
n
250
2max
22 += ⋅  
where max
2
OS  is 100, the Hill coefficient, n, is 2.7 (Kunert, Liard et al. 1996), and the P50 
for rat blood, based on previous studies (Hall 1966; Lahiri 1975; Teisseire, Soulard et al. 
1984; Kunert, Liard et al. 1996; Eichelbronner, Sielenkamper et al. 1999; Zinchuk and 
Dorokhina 2002), is 36 mmHg.  “Virtual” Po2 ( virtualOP 2 ), which is based on standard 
temperature, pH and Pco2 (via base excess, BE), was calculated from microvascular Po2 
measures ( measuredOP 2 ) according to Equation 11:  
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Equation 11 
( )BETpHPvirtual
O m
measuredOP ⋅−−−−+= 0013.0)37(024.0)4.7(48.0log2 21010  
that combines the equations of Severinghaus (1966).  Based on the work of Lash and 
Bohlen (1987), arteriolar pH was assumed to be equivalent to that of carotid arterial 
blood, and venular pH was assumed to be 0.06 (the mean arterial-venous pH difference) 
(Teisseire, Soulard et al. 1984; Powell, Machiedo et al. 1991) less than arterial pH.  
Spinotrapezius muscle temperature was used as spinotrapezius blood temperature (Tm).  
Base excess (BE), which has only a minor impact on the oxyhemoglobin dissociation 
curve, was assumed to be equivalent in both arterial and venous blood. 
Blood flow 
Spinotrapezius blood flow ( STQ ), of both the primary arteriole and venule, was 
calculated from Equation 12, which relates cross-sectional area of the blood vessel and 
average blood velocity:   
Equation 12 
vdQ ST
2
2


= π  
where d and v  are the diameter and mean blood velocity, respectively.  The diameter was 
determined during off-line analysis by measuring the internal width, perpendicular to the 
direction of blood flow, of the vessel on a video monitor, which was calibrated with a 
stage micrometer (Bausch & Lomb, Rochester, NY).  Using a Neofluar 40X/N.A 0.75 
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water immersion objective (Model 46-07-52, Carl Zeiss, Inc.), 1.0 mm on the video 
monitor was equivalent to 0.51 µm on the microscope stage.  The microscope was 
focused on the median plane of the vessel. 
Blood velocity 
As the velocity profile (Figure 14) demonstrates, blood velocity decreases away from the 
longitudinal axis of the vessel (R0).  Pittman and Ellsworth described red blood cell 
velocity with Equation 13 (Pittman and Ellsworth 1986), 
Equation 13 






−= 2
2
0 1)( R
rBvrv  
where r is the radial distance from the axis, v0 is maximal blood velocity (r = 0), B 
describes the bluntness of the profile, which ranges from 0 (plug flow) to 1 (Poiseuille 
parabolic flow), and R is the vessel radius.  This equation forms the basis for deriving 
many of the equations used below for both venular and arteriolar velocity calculations. 
To help determine blood velocity, a 0.1 ml solution (concentration 4.5·108 particles/ml) 
of 2.0 µm FluoSpheres, fluorescent microspheres (F-8827, lot 69A1, Molecular Probes, 
Inc., Eugene, OR), were injected via the jugular venous catheter for each time point 
measured (Rovainen, Wang et al. 1992; Vovenko, Golub et al. 2002).  To prevent 
hypotensive episodes due to the anti-aggregate compound, Tween-20, the FluoSpheres 
were prepared as described in Appendix V.  For blood velocity measurements, these 
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FluoSpheres were briefly excited by a 100 Hz flash illumination.  Since the VCR 
captures video frames at a rate of 30 Hz, each microsphere produced a train of 
approximately three particle images on a single video frame.   
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R
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Figure 14. Longitudinal section of vessel, demonstrating bluntness of the velocity 
profile (B), vessel radius (R), longitudinal axis of vessel (R0), and middle one-third of 
vessel (W). 
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Depth of field 
The depth of field (D) for the objective was calculated to be 0.62 µm using Equation 14 
and Equation 15, from Slayter (1970),  
Equation 14 
α
αλ
2sin
cos61.0
n
D =   
Equation 15 


= −
n
N.A.sin 1α   
where λ is the emission wavelength from the FluoSphere, 515 nm, α is the aperture, or 
vertex angle, 34°, and n is the refractive index of water, 1.337 (Figure 15).  Thus, 
microspheres within ± 0.31 µm of the image plane will appear in focus.  Whether the 2-
µm diameter fluorescent particles were in focus was determined subjectively by the 
quality of the image, and objectively by the size of the microsphere image on the video 
monitor; “in-focus” microspheres have an on-screen diameter of ~4 mm (see above).  
This method of determining if RBCs or microspheres are in the median plane has been 
validated by Bishop et al (2001) and Tangelder et al (1986). 
68
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Figure15.Depthoffield(D)andapertureangle(a).
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Venular blood velocity 
In venules, where velocity is slower, maximal blood velocity was determined.  The 
distance between in-focus microspheres on the median plane of the vessel and within the 
middle one-third of the vessel (W) (Figure 16) allowed for determination of particle 
(fluorescent microsphere) velocity (vp) during off-line analysis, using Equation 16: 
Equation 16 
t
n
d
v
t
p



−= 1    
where dt is the total distance between the first and last image of a single particle captured 
in a video frame, n is the number of times a microsphere appears in that frame, and t is 
0.01 seconds (the time between flashes for 100 Hz excitation).  The average velocity, 
weighted by particle frequency ( *v ), was determined by averaging the velocities of 
approximately 10 different particles (vp).  The result of the arithmetic average of the 
particle velocities is a value that is weighted by particle velocity, since the number of 
particles passing through the observation region is proportional to their individual 
velocities.  
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Figure 16. Cross section of vessel, demonstrating median plane, vessel radius (R) 
and the middle one-third of vessel (W). 
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Mean blood velocity ( v ) was calculated from *v using Equation 17 (Pittman 2004), 
Equation 17 

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Observing venules in the rat spinotrapezius muscle, Bishop et al (2001) reported values 
for B ranging from 0.9 to 1.1; thus, my calculations will assume that B is 1, Poiseuille 
flow.  In addition, W/2R (Figure 16) was arbitrarily set to be 0.33. 
Arteriolar blood velocity 
In arterioles, the blood velocity was often so fast that, at a 100-Hz flash rate, centerline 
microspheres often appeared only once, and thus, their velocity could not be calculated.  
When this occurred, a slightly different methodology and equation were used.  Instead of 
measuring central particle velocities, individual particle velocities (vp) were determined 
on the median plane outside of the center one-third of the vessel, the area excluding W 
(Figure 16).  Again, averaged velocity, weighted by particle velocity ( *v ) was 
determined by averaging the velocities of approximately 10 different particles.    
In this case, assuming B = 1, mean blood velocity was calculated using Equation 18 
(Pittman 2004), 
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Equation 18 
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This equation assumed that the depth of field was much less than the radius of the vessel; 
this was an appropriate assumption given that the depth of field was 0.62 µm and the 
radius was approximately 50 µm. 
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Muscle Contraction and Contractile Measures 
The muscle contractions were initiated via a muscle stimulator (A310 Accupulser pulse 
generator and A360 high voltage stimulus isolator, World Precision Instruments, Inc., 
Sarasota, FL) connected to the exteriorized spinotrapezius muscle by two silver/silver 
chloride electrodes.  The electrodes were fabricated from thin strips of an electrically 
conductive polymer coated film (114-26 B, Creative Materials, Inc., Tyngsboro, MA) and 
insulated 20-gauge wire connected by an electrically conductive epoxy (GPC 251, 
Creative Materials, Inc.). 
Muscle force was measured with a Grass force-displacement transducer (model FT03C, 
Grass Instrument Co.), which has a linear sensitivity of 2 mg to 10 kg and a resonant 
frequency of 85 Hz; the transducer previously demonstrated a linear relationship between 
voltage and mass (Figure 17).  Twenty-gauge wire was used to connect the wire support 
of the spinotrapezius muscle directly to the force transducer (Figure 9).  The force 
transducer was attached to a tension adjuster mounted on the animal platform, which was 
used to optimize muscle length (Lo) during whole muscle isometric twitch contractions.  
During preliminary tests, it was determined that Lo occurred at a preload of ~3 g, which is 
in agreement with the results of Suzuki et al (1995).  
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Figure 17. Force transducer calibration curve 
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Signals from the force transducer were sent to a general purpose transducer amplifier 
(DA-100C, BIOPAC Systems, Inc., Goleta, CA; gain of 200 and with a 10 and 100 Hz 
low pass filter) and high-speed data acquisition system (MP150, BIOPAC) via a six-pin 
Grass cable and transducer connector interface (TCI-100, BIOPAC), and then to a 
desktop computer for continuous on-line data acquisition at a rate of 100 Hz 
(AcqKnowledge software, v3.7.3, BIOPAC). 
Peak force measurements were obtained during 200 msec stimulation at 80 Hz.  In 
addition, muscle force was continuously acquired during a three-minute muscle 
stimulation protocol.  This protocol involved contractions at a rate of one contraction per 
second; each contraction was stimulated by a 9-pulse (0.5 msec pulse duration) constant-
frequency train delivered over 200 msec (40 Hz) (Figure 18), which was verified using a 
digital oscilloscope (TDS 2002, Tektronix, Beavertown, OR).  From this recording, 
isometric muscle “work” and fatigue index were calculated.   
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Figure 18. Stimulation protocol, where A) is an individual pulse, B) is a train of nine 
individual pulses, and C) is series of pulse trains (note the different time scales).
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The force-time integral (FTI): 
Equation 19 
∫ ⋅= 180
0
dtFW  
was used to quantify isometric muscle work (W) based on force (F) and time (Rome and 
Kushmerick 1983; Russ, Elliott et al. 2002).  FTI was calculated from the force curves 
(Figure 19) using Origin 7.05 (OriginLab Corp., Northhampton, MA), and normalized to 
the estimated muscle cross-sectional area (CSA) in cm2: 
Equation 20 
0L
mCSA ⋅= ρ . 
where m is mass in grams, ρ is density, assumed to be 1.05 g·cm-2 (Rome and 
Kushmerick 1983), and L0 is muscle length in centimeters, to give a final quantity in 
N·s/cm2. 
Fatigue index (FI) (Burke, Levine et al. 1973) was calculated as the percent decline in 
force from its peak to the last contraction of the three-minute protocol (Equation 21) 
(higher values mean less fatigue). 
Equation 21 
peak
terminal100
F
FFI ⋅=
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Figure 19. Representative spinotrapezius force tracing, from which force-time 
integral and fatigue index were calculated. 
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Specific protocols 
The following details the experimental protocol for each phase.  For all animals, PaO2 and 
PaO2/FIO2 ratio, an index of respiratory function (Sheridan, Zapol et al. 1999), was used to 
assess the degree of hypoxemia and indirectly quantify the severity of emphysema or 
other respiratory pathology.  While a normal PaO2/FIO2 ratio should be ~500 (100/0.21), 
values of less than 300, 200, or 100 indicate a mild, moderate, or severe gas exchange 
impairment, likely due to intrapulmonary shunting and lung injury (Artigas, Bernard et 
al. 1998). 
Phase I 
Experiments were conducted on groups of animals 4, 8, 12, 16, or 20 weeks following the 
initial instillation of either elastase or saline to help determine the time course of any 
changes in arterial blood gases or transformation of muscle fiber types.  After initial 
anesthesia and oral endotracheal intubation (described on pages 39 and 40, respectively), 
the animal was placed on a small animal ventilator set for a FIO2 of 0.21 (room air), 
respiratory rate (RR) of 60 breaths per min (bpm), and inspiratory pressure of 10-12 
cmH2O.  Pilot testing revealed that these settings resulted in normal ventilation as 
determined by arterial pH and PCO2.   
Following 20 minutes of recovery and equilibration on the ventilator, and after femoral 
arterial cannulation, a normoxic arterial blood sample was withdrawn into a 100 µl 
capillary tube and analyzed in both a blood gas analyzer (ABL 705, Radiometer, 
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Denmark) to measure blood gas values (pH, PaO2, PaCO2), electrolytes (K
+, Na+, Ca+2, and 
Cl-) and metabolites (glucose and lactate), and a co-oximeter (OSM 3 Hemoximeter, 
Radiometer) to measure tHb, COHb, MetHb, oxy-Hb, deoxy-Hb, and SO2.  To simulate a 
fall in PaO2 (hypoxic condition), as occurs during whole body exercise in patients with 
emphysema, the FIO2 was reduced to 0.15 and the animal given 20 minutes to equilibrate 
before withdrawing a hypoxic arterial blood sample.   
At this point the animal was euthanized and the right spinotrapezius and soleus muscles 
were immediately removed and processed as previously described (page 44). 
Phase II 
For microcirculatory and muscle physiology experiments, animals were randomized 
approximately 62 weeks after elastase or saline instillation.  The force transducer and 
pressure transducers were calibrated at two points prior to each experiment.  After initial 
anesthesia and cannulations, the spinotrapezius muscle was prepared as previously 
described (page 10), and the animal was transferred to the thermostatic animal platform.  
The spinotrapezius muscle was positioned, ventral surface facing up, on the viewing 
pedestal of the platform, connected to the force transducer, moistened with normal saline 
and the covered with Saran film (S.C. Johnson & Sons, Inc. Racine, WI) to prevent 
desiccation and minimize atmospheric gas exchange. 
After the platform was securely placed on the microscope, carotid arterial and jugular 
venous cannulae were connected to their respective pressure transducers, and muscle 
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tension adjusted to Lo; these parameters were continuously recorded on an electronic 
chart recorder (Biopac), as previously described, for the duration of the experiment.  
After peak force was measured from a twitch contraction (80 Hz for 200 msec), capped 
Tygon tubing was placed over the tracheostomy tube to deliver a FIO2 of either 0.21 or 
0.40 at a rate of 0.4 liters per minute.  The animal was given at least 15 minutes to 
recover from surgery and equilibrate to its FIO2.  In the meantime, the Pd-MTCPP and 
FluoSphere solutions (Appendices III and V, respectively) were warmed to greater than 
room temperature, and the primary feed arteriole and venule were located under the 
microscope.  Prior to baseline microvascular measures and the muscle contraction 
protocol, an arterial blood gas sample was drawn from the carotid artery and immediately 
analyzed (as described above), the Pd-MTCPP solution was injected via the femoral vein, 
and vital signs (body temperature, heart rate, systolic and diastolic blood pressure, and 
mean arterial pressure were measured.  A continuous video recording of the 
microcirculation was made. 
Baseline arteriolar and venular PO2 measurements were made using the phosphorescence 
quenching method (page 54), followed by a 0.1-0.2 ml injection of FluoSpheres via the 
femoral vein, and blood velocity and diameter recorded as described above (“Blood 
flow,” page 63).  Immediately after a three-minute stimulation protocol, as described 
above (“Muscle Contraction and Contractile Measures,” page 73), another 0.1-0.2 ml 
injection FluoSpheres was administered and blood velocity, vessel diameter, and 
microvascular PO2 measurements were made, as well as five minutes after the end of the 
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contraction.  The FIO2 was then changed to either 0.21 or 0.40, and the animal given 15 
minutes to recover and equilibrate.  Baseline vital signs and microvascular measures were 
taken again, and the stimulation protocol and microvascular measures were repeated as 
previously described. 
After the animal was euthanized, the spinotrapezius muscle was removed and weighed, a 
thoracic necropsy was performed, and the heart and lungs removed en bloc, inflated and 
photographed. 
Statistical Analysis 
Data in text and tables are presented as mean ( x ) and standard deviation (SD), and 
graphic data are presented as mean values with bars or bands representing a 95% 
confidence interval.  JMP version 4.0.4 (SAS Institute, Inc., Cary, NC) was used to 
perform significance tests (analyses of variance on multiple factors and t-tests on two 
independent means); actual p values are reported with the level of significance set at 0.05.  
Reporting in this manner is in accordance with established recommendations (Streiner 
1996; Curran-Everett, Taylor et al. 1998), as well as the American Physiological 
Society’s guidelines (Curran-Everett and Benos 2004).  
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Results 
 
Phase I 
Experimental animals 
During pilot studies, as the instillation technique was being developed, five consecutive 
animals died during or immediately after the instillation procedure (one elastase, four 
saline); Poole (2002) had warned of this possibility.  However, for no known reason, 
these were the last procedure-related fatalities.  No other animals died prior to the final 
experiment.   
Sixty-one animals were used in phase I, and data were available for 56 (two were taken 
by the Division of Animal Resources for testing, two died during the terminal 
experiment, and one animal is unaccounted for).  As seen in Table 3, Student’s t-test 
found no differences between elastase and saline groups with regard to age at instillation 
(p = 0.57), initial or final body mass (p = 0.75 and 0.78, respectively), or weight gain (p = 
0.96) between initial instillation and the terminal experiment.  Likewise, a two-way 
analysis of variance (ANOVA) found no effect (p = 0.18) for baseline body mass with 
respect to experimental group (elastase vs. saline) and time after instillation (weeks) 
(Table 4).   
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Figure 20 illustrates the change in mass between groups over time.  In addition, soleus 
and spinotrapezius muscle masses were equivalent between experimental groups (p = 
0.31 and 0.74, respectively).  Over time, the only difference was found in the 
spinotrapezius muscle, which was lighter at four weeks after instillation than at eight, 12, 
16, or 20 weeks (Figure 21) (p < 0.01 to 0.04).   
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Table 3.  Baseline characteristics. 
Group n Age at instillation
(weeks) 
Initial mass 
(g) 
Final mass 
(g) 
Difference 
(g) 
Elastase 30 10.8 (SD 0.7) 213.7 (SD 16.2) 266.4 (SD 31.9) 52.8 (SD 32.8)
Saline 25 10.7 (SD 0.7) 214.9 (SD 11.3) 268.5 (SD 22.8) 53.6 (SD 24.5)
Total 55 10.8 (SD 0.7) 214.2 (SD 14.1) 267.4 (SD 27.9) 53.2 (SD 29.0)
 
 
Table 4.  Final body mass (g) for each time interval.  
Group 4 weeks 8 weeks 12 weeks 16 weeks 20 weeks 
Elastase 234 (SD 10.9) 275 (SD 12.0) 268 (SD 10.1) 280 (SD 10.9) 278 (SD 12.0)
Saline 267 (SD 10.9) 257 (SD 15.4) 276 (SD 12.0) 265 (SD 12.0) 273 (SD 10.9)
Total 250 (SD 7.7) 266 (SD 9.8) 272 (SD 7.8) 272 (SD 8.1) 275 (SD 8.1) 
 
   86 
 
12 14 16 18 20 22 24 26 28 30 32 34
200
220
240
260
280
300
320
340
360
380
400
B
od
y 
m
as
s 
(g
)
Age (weeks)
 Elastase
 Saline
 
Figure 20. Growth curve. 
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Figure 21. Soleus and spinotrapezius muscle masses over time. 
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To qualitatively assess whether or not the elastase instillation was producing emphysema, 
two animals had ventral-dorsal (Figures 22 and 23) and lateral chest radiographs (Figures 
24 and 25) taken approximately 19 weeks after the instillation of either elastase or saline; 
it is fairly obvious that the rostral-caudal, lateral, and ventral-dorsal dimensions are larger 
in the elastase instilled animal, consistent with emphysema.  Arterial PaO2 and PaO2/FIO2 
ratio were used to quantitatively determine the severity of emphysema and the resulting 
hypoxemia (refer to “Arterial blood gases,” page 91). 
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Figure 22. Ventral-dorsal chest radiograph of saline instilled rat. 
 
Figure 23. Ventral-dorsal chest radiograph of elastase instilled rat. 
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Figure 24. Lateral chest radiograph of saline instilled rat. 
 
Figure 25. Lateral chest radiograph of elastase instilled rat. 
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Arterial blood gases 
With the exception of arterial PO2, PaO2/FIO2 ratio, and glucose and lactate concentrations, 
arterial blood gas analysis revealed no differences between groups (elastase vs. saline) 
with regard to blood gases, acid-base status, hemoglobin, or electrolytes breathing either 
FIO2 0.21 (Table 5, Figure 26), or FIO2 0.15 (Table 6, Figure 27).   
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Table 5.  Phase I arterial blood gas data on FIO2 0.21. 
 Elastase Saline p value 
pH 7.43 (SD 0.03) 7.44 (SD 0.03) 0.49 
PaCO2 (mmHg) 40 (SD 3.4) 38.5 (SD 4.3) 0.07 
PaO2 (mmHg) 77 (SD 10.7) 90 (SD 21.6) <0.01 
PaO2/FIO2 365 (SD 51) 427 (SD 103) <0.01 
HCO3- (mmol/l) 26 (SD 0.9) 26 (SD 1.5) 0.08 
SaO2 (%) 93 (SD 4.3) 94 (SD 6.7) 0.51 
tHb (g/l) 140 (SD 7.4) 142 (SD 6.8) 0.19 
K+ (meq/l) 3.8 (SD 0.3) 3.8 (SD 0.2) 0.78 
Na+ (meq/l) 137 (SD 1.6) 136 (SD 1.4) 0.40 
Ca+2 (meq/l) 2.2 (SD 0.2) 2.1 (SD 0.2) 0.57 
Cl- (meq/l) 99 (SD 2.4) 99 (SD 1.8) 0.71 
Glucose (mg/dl) 224 (SD 31.2) 250 (SD 59.6) 0.04 
Lactate (mmol/l) 1.0 (SD 0.4) 1.5 (SD 1.2) 0.04 
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Figure 26. Arterial PO2 at 4, 8, 12, 16, and 20 weeks; FIO2 = 0.21. 
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Table 6.  Phase I arterial blood gas data on FIO2 0.15. 
 Elastase Saline p value 
pH 7.42 (SD 0.07) 7.44 (SD 0.04) 0.31 
PaCO2 (mmHg) 41 (SD 8.2) 39 (SD 4.3) 0.22 
PaO2 (mmHg) 57 (SD 9) 67 (SD 12) <0.01 
PaO2/FIO2 377 (SD 61) 449 (SD 77) <0.01 
HCO3- (mmol/l) 26 (SD 2.1) 26 (SD 1.3) 0.75 
SaO2 (%) 84 (SD 12.3) 90 (SD 7.7) 0.06 
tHb (g/l) 139 (SD 7) 142 (SD 7) 0.12 
K+ (meq/l) 4.0 (SD 0.3) 4.1 (SD 0.2) 0.31 
Na+ (meq/l) 136 (SD 2) 136 (SD 2) 0.65 
Ca+2 (meq/l) 2.2 (SD 0.2) 2.2 (SD 0.2) 0.51 
Cl- (meq/l) 99 (SD 2) 99 (SD 2) 0.51 
Glucose (mg/dl) 225 (SD 58) 233 (SD 74) 0.66 
Lactate (mmol/l) 1.3 (SD 0.9) 1.0 (SD 0.5) 0.30 
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Figure 27. Arterial PO2 at 4, 8, 12, 16, and 20 weeks; FIO2 = 0.15. 
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MHC isoforms 
SDS-PAGE (Figure 28) was used to differentiate the various MHC isoforms, and a 
densitometric analysis (Figure 29) was used to determine the relative proportions of each.  
The only statistically significant difference in MHC isoforms between experimental 
groups was a decrease in spinotrapezius MHC IIx, which was lower in the elastase group 
(p = 0.01); however, the slight increases in other MHC isoforms were not significant 
(Table 7).  A two-way ANOVA for each MHC isoform found no interaction between 
experimental group (elastase vs. saline) and age (14, 18, 22, 26, or 30 weeks old) (p = 
0.08 to 0.83).  However, it did reveal differences in soleus muscle MHC expression with 
age for types I, IIa, and IIb (p = 0.0002, 0.05, and 0.006, respectively), but not IIx (p = 
0.58) (Figure 30).  In addition, spinotrapezius muscle MHC expression of type I, IIa, and 
IIx changed with age (p = 0.03, <0.01, and 0.02, respectively); there were no differences 
in IIb expression between age groups (p = 0.25) (Figure 31).   
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Figure 28. Representative soleus SDS-PAGE with arrows at reference molecular 
weights and MHC bands (~200 kDa).  A, C, and D are 22, 18, and 26 wk old saline 
instilled animals, B is a 22 wk old elastase instilled animal. 
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Figure 29. Representative densitometric analysis used to determine proportions of 
MHCs I, IIa, IIb, and IIx.  Curves A – D correspond to the lanes labeled A – D in 
Figure 28. 
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Table 7.  Percentage of MHC isoforms in elastase vs. saline instilled animals for all 
age groups. 
 Elastase (n = 21) Saline (n = 13) p value 
Soleus m.     
I 9% (SD 1) 9% (SD 1) 0.69 
IIa 10% (SD 6) 11% (SD 9) 0.86 
IIx 63% (SD 7) 62% (SD 10) 0.77 
IIb 18% (SD 6) 18% (SD 4) 0.88 
Spinotrapezius m.     
I 17% (SD 7) 16% (SD 7) 0.55 
IIa 10% (SD 12) 6% (SD 4) 0.35 
IIx 40% (SD 12) 51% (SD 9) 0.01 
IIb 33% (SD 9) 27% (SD 7) 0.07 
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Figure 30. Soleus muscle MHC proportions by age. 
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Figure 31. Spinotrapezius muscle MHC proportions by age. 
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Phase II 
Experimental animals 
There was no difference in body mass between elastase and saline groups ( x  = 294 g (SD 
37) vs. 296 g (SD 22), respectively; p = 0.15).  In addition, there were no differences in 
baseline vital signs between groups (Table 8).  A matched pairs analysis also revealed no 
differences in heart rate (HR), respiratory rate (RR), mean arterial pressure (MAP), or 
body temperature between the exercise bouts on FIO2 0.21 versus 0.40 (p = 0.87, 0.42, 
0.71, and 0.57, respectively), which indicates that the physiological conditions under 
which the animals performed each exercise bout were similar.   
Initially, injection of 0.5 ml FluoSpheres caused a rapid and dramatic drop in blood 
pressure, severe enough to lead to death in a few preliminary experiments.  Smaller doses 
(0.1 ml) still led to a substantial decline in blood pressure, which took several minutes to 
return to baseline (Figure 32).  Eventually, it was determined that the anti-aggregation 
agent, Tween-20, was responsible (Figure 33). 
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Table 8.  Baseline vital signs on FIO2 0.21 and 0.40. 
 Elastase Saline p value 
FIO2 0.21 0.40 0.21 0.40 E vs. S 
0.21 
HR 
(beats/min) 
297 (SD 51) 285 (SD 66) 333 (SD 59) 327 (SD 65) 0.29
RR 
(breaths/min) 
81 (SD 28) 57 (SD 12) 63 (SD 31) 67 (SD 10) 0.35
MAP (mmHg) 92 (SD 14) 92 (SD 15) 97 (SD 11) 97 (SD 15) 0.51
Body 
temp. (° C) 
37.1 (SD 0.9) 37.1 (SD 0.7) 36.5 (SD 1.0) 36.5 (SD 0.9) 0.32
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Figure 32. Arterial blood pressure tracing, demonstrating a dramatic hypotensive 
episode with each injection of FluoSpheres without Tween removed. 
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Figure 33. Arterial pressure tracing, demonstrating no hypotension after injection 
of either 1) FluoSpheres with Tween removed, or 2) normal saline, but significant 
hypotension when supernatant from diluted and centrifuged FluoSpheres is 
injected. 
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Lung pathology 
Due to the surprisingly low systemic PaO2 values from phase I as well as anecdotal 
reports throughout this and other research universities, the lungs from each animal were 
grossly necropsied to determine if the animal had a lung pathology (i.e., Rat respiratory 
virus) other than elastase-induced emphysema.  No animal had normal looking lungs, 
and, if anything, the lungs from the saline group (Figure 34) looked even “less healthy” 
than those from the elastase group (Figure 35).   
There does not appear to be a close relationship between severity of lung injury and PaO2, 
although the animal with the highest PaO2 (Figure 35, B) appears to have a segmental 
(dorsal caudal and dorsal cranial) pattern of consolidation as opposed to the other lungs 
which show a more diffuse infiltration.  Although not entirely obvious from these figures, 
there did appear to be a consistent pattern in which the right dorsal-caudal and dorsal-
cranial segments demonstrated more infiltrate, with relative sparing of the left lung, and 
more medial and ventral segments of both the cranial and caudal lobes. 
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Figure 34. Lungs from necropsy of saline instilled animals, which had the following 
PaO2's (mmHg):  A) 70, B) 96, C) 49, D) 79, and E) 62. 
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Figure 35. Lungs from necropsy of elastase instilled animals, which had the 
following PaO2's (mmHg):  A) 64, B) 66, C) 66, D) 59, E) 49, and F) 72. 
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Arterial blood gases 
Unfortunately, due to the lung pathology so prevalent in the animals in this study, both 
the elastase and saline groups were almost equally hypoxemic ( x  PaO2 62 (SD 6.6) vs. 69 
(SD 17.1), respectively with FIO2 0.21, p = 0.36), although on room air, only the elastase 
group had a PaO2/FIO2 < 300 (Table 9).  However, both groups had a PaO2/FIO2 < 300 
when breathing FIO2 0.40 (Table 10), indicating a mild gas exchange impairment.  In fact, 
only one animal out of the 14, from the control group, had a room air PaO2 of > 80 
mmHg.   
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Table 9.  Phase II arterial blood gas data on FIO2 0.21. 
 Elastase (n = 8) Saline (n = 6) p value 
pH 7.44 (SD 0.04) 7.40 (SD 0.07) 0.17 
PaCO2 (mmHg) 35 (SD 6.1) 43 (SD 10.1) 0.12 
PaO2 (mmHg) 62 (SD 6.6) 69 (SD 17.1) 0.36 
PaO2/FIO2 297 (SD 31.3) 327 (SD 82) 0.36 
HCO3- (mmol/l) 25 (SD 0.9) 25 (SD 1.5) 0.63 
SaO2 (%) 87 (SD 5.3) 88 (SD 7.1) 0.81 
tHb (g/l) 121 (SD 5.9) 123 (SD 6.5) 0.52 
K+ (meq/l) 3.6 (SD 0.3) 3.8 (SD 0.6) 0.58 
Na+ (meq/l) 142 (SD 2.3) 140 (SD 2.5) 0.16 
Cl- (meq/l) 107 (SD 2.3) 104 (SD 2.4) 0.04 
Glucose (mg/dl) 228 (SD 58) 278 (SD 88) 0.23 
Lactate (mmol/l) 1.7 (SD 0.4) 1.9 (SD 0.9) 0.59 
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Table 10.  Phase II arterial blood gas data on FIO2 0.40. 
 Elastase Saline p value 
pH 7.39 (SD 0.03) 7.35 (SD 0.08) 0.24 
PaCO2 (mmHg) 43 (SD 3.2) 49 (SD 11.0) 0.14 
PaO2 (mmHg) 89 (SD 11) 107 (SD 8) 0.01 
PaO2/FIO2 224 (SD 28) 268 (SD 20) 0.01 
HCO3- (mmol/l) 25 (SD 1.0) 24 (SD 1.0) 0.59 
SaO2 (%) 96 (SD 2.8) 98 (SD 2.0) 0.24 
tHb (g/l) 126 (SD 4.6) 126 (SD 8.0) 0.93 
K+ (meq/l) 3.7 (SD 0.3) 3.7 (SD 0.4) 0.75 
Na+ (meq/l) 141 (SD 2.1) 141 (SD 1.9) 0.87 
Cl- (meq/l) 105 (SD 2.1) 104 (SD 2.7) 0.44 
Glucose (mg/dl) 228 (SD 72) 230 (SD 64) 0.97 
Lactate (mmol/l) 1.2 (SD 0.4) 1.6 (SD 0.6) 0.25 
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Oxygen delivery to and consumption by the spinotrapezius muscle 
Microvascular PO2  
Using phosphorescence quenching microscopy, arteriolar and venular PO2 were measured 
in the spinotrapezius (ST) muscle at rest, immediately after a three-minute contraction, 
and five minutes after contraction (time 0, 3, and 8, respectively, on the subsequent 
graphs) with the animal breathing a FIO2 of 0.21 (Figures 36 and 37) or 0.40 (Figures 38 
and 39).  With the exception of first post-contraction venular PO2 on FIO2 0.21, and both 
the baseline arteriolar and venular PO2 on FIO2 0.21 (p = 0.04, 0.02, and 0.03, 
respectively), PO2 was equivalent between groups.  In addition, a repeated measures 
analysis revealed statistically equivalent arteriolar and venular PO2 across all time points, 
for both FIO2 0.21 and 0.40 (p = 0.15 – 0.92).  
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Figure 36. Arteriolar PO2 before (time = 0) and after a three-minute contraction 
(time = 3 and 8); FIO2 = 0.21. 
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Figure 37. Venular PO2 before (time = 0) and after a three-minute contraction (time 
= 3 and 8); FIO2 = 0.21. 
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Figure 38. Arteriolar PO2 before (time = 0) and after a three-minute contraction 
(time = 3 and 8); FIO2 = 0.40. 
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Figure 39. Venular PO2 before (time = 0) and after a three-minute contraction (time 
= 3 and 8); FIO2 = 0.40. 
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Spinotrapezius blood flow 
Linear regression of all time matched arteriolar flow ( STaQ ) and venular flow ( STvQ ) 
measurements (n = 42) revealed a relatively strong correlation (r = 0.68, p < 0.01) (Figure 
40).  Because arteriolar flow had a greater number of complete data sets compared to 
arteriolar flow (n = 54 vs. 43), as well as a lower degree of variability ( x  = 25 nl/sec (SD 
15.7) vs. 26 nl/sec (SD 18.2), arteriolar flow was used as ST blood flow in hypothesis 
testing, and for calculating oxygen consumption. 
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Figure 40. Scatterplot and regression line (red) of spinotrapezius arteriolar vs. 
venular flow for all matching time points (n = 42), which demonstrates a slope of 
0.61 and correlation of 0.68 (p < 0.01) compared to the identity line (green), where 
ST
v
ST
a QQ = . 
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Tables 11 and 12 report the measured (diameter and blood velocity) and calculated 
(blood flow) arteriolar parameters at baseline, and immediately following a three minute 
contraction, respectively; there were no differences between experimental groups.  Blood 
velocity was also unchanged when comparing baseline to post-contraction measures (p = 
0.57), thus making increased diameter (p = 0.04) almost solely responsible for the 
increase in flow (p = 0.08).   
There were no statistical differences in ST arterial (Figure 41) or venular flow (Figure 
42) between groups (elastase vs. saline) at any time point (time = 0, 3, and 8 minutes) 
while breathing FIO2 0.21 (p = 0.81, 0.20 and 0.92, and p =0.83, 0.37 and 0.68, 
respectively).  In addition, breathing FIO2 0.40 (Figure 43) did not have an effect on flow, 
either between groups at any time point (p = 0.32, 0.48, and 0.63) or when compared to 
the same group breathing FIO2 0.21 (p = 0.31, 0.99, and 0.08).  However, there was an 
increase in ST flow immediately after contraction for both groups breathing FIO2 0.21 and 
0.40 (time 0 vs. 3, p = 0.08 and 0.02, respectively), which returned to resting values 
within five minutes after the contraction (time 0 vs. time 8, p = 0.27 and 0.22, 
respectively). 
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Table 11.  Primary arteriolar blood flow parameters at baseline. 
  Elastase Saline 
 FIO2 0.21      p value 
Blood velocity (mm/sec) 3.4 (SD 1.7) 3.9 (SD 1.9) 0.68 
Diameter (µm) 73 (SD 10.5) 84 (SD 28.0) 0.45 
Blood velocity (mm/sec) 3.4 (SD 1.7) 3.9 (SD 1.9) 0.68 
       
 FIO2 0.40      
Blood flow (nl/sec) 18.3 (SD 11.1) 25.5 (SD 9.5) 0.32 
Diameter (µm) 67 (SD 14.2) 79 (SD 21.8) 0.32 
Blood velocity (mm/sec) 4.3 (SD 2.0) 4.9 (SD 1.3) 0.65 
 
Table 12.  Primary arteriolar blood flow parameters immediately post-contraction. 
  Elastase Saline 
 FIO2 0.21      p value 
Blood flow (nl/sec) 26.5 (SD 19.7) 49.5 (SD 17.7) 0.20 
Diameter (µm) 97 (SD 15.7) 100 (SD 28.2) 0.84 
Blood velocity (mm/sec) 3.1 (SD 1.9) 4.1 (SD 1.1) 0.52 
       
 FIO2 0.40      
Blood flow (nl/sec) 28.6 (SD 23.2) 37.8 (SD 9.1) 0.48 
Diameter (µm) 88 (SD 15.0) 91 (SD 12.0) 0.69 
Blood velocity (mm/sec) 3.7 (SD 2.2) 5.3 (SD 1.4) 0.25 
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Figure 41. Arteriolar blood flow before (time = 0) and after a three-minute 
contraction (time = 3 and 8); FIO2 = 0.21. 
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Figure 42. Venular blood flow before (time = 0) and after a three minute contraction 
(time = 3 and 8); FIO2 = 0.21. 
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Figure 43. Arteriolar blood flow before (time = 0) and after a three minute 
contraction (time = 3 and 8); FIO2 = 0.40. 
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Oxygen consumption 
Spinotrapezius oxygen consumption ( STOV 2
 ) was calculated from spinotrapezius blood 
flow and arteriolar-venular oxygen difference (as previously described, page 10) and 
converted to µl of O2 per min.  STOV 2
  was equivalent between elastase and saline animals 
across all time intervals and conditions (FIO2) (p = 0.18 to 0.86) (Figures 44 and 45).  
Although Figures 44 and 45 illustrate a trend towards increased STOV 2
  immediately after 
contraction, a scatterplot of the data (Figure 46) reveals that a single outlier is primarily 
responsible for the elevated STOV 2
  for the saline group immediately post contraction.  
When the data were analyzed to determine if there was an increase in STOV 2
  with 
supplemental oxygen, only the final resting measurement on FIO2 0.40 (0.05 µl/min) was 
significantly higher than when breathing FIO2 0.21 (0.02 µl/min; p = 0.04 for time = 8, 
versus p = 0.28 and 0.36 for time 0 and 3, respectively).  
Table 13 and Table 14 demonstrate the contributions of blood flow (convective oxygen 
delivery) and oxygen extraction (diffusive oxygen delivery) to STOV 2
 .  Surprisingly, 
although not statistically significant, blood flow was greater in the saline group, while 
oxygen extraction was higher in the elastase group (Figures 47 and 48). 
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Figure 44. Spinotrapezius muscle oxygen consumption before (time = 0) and after a 
three-minute contraction (time = 3 and 8); FIO2 = 0.21. 
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Figure 45. Spinotrapezius muscle oxygen consumption before (time = 0) and after a 
three-minute contraction (time = 3 and 8); FIO2 = 0.40. 
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Figure 46. Scatterplot for oxygen consumption (FIO2 = 0.21), indicating a single 
outlier at 0.22 µl/min. 
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Table 13.  Baseline STOV 2
  and the respective contributions of blood flow and O2 
extraction. 
  Elastase Saline 
 FIO2 0.21      p value 
ST
OV 2
  (µl/min) 0.035 (SD 0.015) 0.032 (SD 0.024) 0.86 
Blood flow (nl/sec) 16.8 (SD 12.6) 18.4 (SD 5.6) 0.82 
O2 extraction 0.51 (SD 0.16) 0.29 (SD 0.22) 0.06 
       
 FIO2 0.40      
ST
OV 2
  (µl/min) 0.039 (SD 0.026) 0.070 (SD 0.054) 0.27 
Blood flow (nl/sec) 18.3 (SD 11.1) 25.5 (SD 9.5) 0.32 
O2 extraction 0.35 (SD 0.21) 0.23 (SD 0.16) 0.29 
 
Table 14.  Immediate post-contraction STOV 2
  and the respective contributions of blood 
flow and O2 extraction. 
  Elastase  Saline 
 FIO2 0.21      p value 
ST
OV 2
  (µl/min) 0.034 (SD 0.027) 0.117 (SD 0.106) 0.18 
Blood flow (nl/sec) 26.5 (SD 19.7) 49.5 (SD 17.7) 0.20 
O2 extraction 0.50 (SD 0.24) 0.29 (SD 0.16) 0.13 
       
 FIO2 0.40      
ST
OV 2
  (µl/min) 0.072 (SD 0.077) 0.100 (SD 0.061) 0.62 
Blood flow (nl/sec) 28.6 (SD 23.2) 37.8 (SD 9.1) 0.48 
O2 extraction 0.33 (SD 0.30) 0.23 (SD 0.08) 0.45 
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Figure 47. Oxygen extraction fraction of the spinotrapezius m.; FIO2 = 0.21. 
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Figure 48. Oxygen extraction fraction of the spinotrapezius m.; FIO2 = 0.40. 
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Muscle performance  
Although room air (FIO2 0.21) indices of muscle performance were statistically equivalent 
between groups (Table 15 and Figure 49), the saline group had consistently higher peak 
force, force-time integral, and fatigue index values.  Although there was no statistical 
benefit when breathing supplemental oxygen (FIO2 0.40) on either the force-time integral 
or fatigue index (p = 0.39 and 0.85, respectively), the force time integral did increase 
~18% for both groups.   
There was a positive correlation between spinotrapezius muscle oxygen consumption and 
“muscle work,” the force-time integral (Figure 50).  Although no significant relationship 
between fatigue index (FI) and oxygen consumption (Figure 51), there was a trend 
toward less fatigue (higher FI) with lower STOV 2
 .  There was also no relationship between 
the force-time integral and fatigue index (p = 0.48).   
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Table 15.  Indices of ST muscle performance (Elastase vs. Saline). 
  Elastase Saline 
 FIO2 0.21      p value 
Force-time integral 
(N·s/cm2) 1.33 (SD 0.95) 2.38 (SD 1.21) 0.14 
Fatigue index (%) 55 (SD 27) 62 (SD 19) 0.66 
 FIO2 0.40      
Force-time integral 
(N·s/cm2) 1.58 (SD 0.74) 2.79 (SD 0.99) 0.05 
Fatigue index (%) 51 (SD 23) 67 (SD 19) 0.25 
    
Mass (g) 0.37 (SD 0.04) 0.43 (SD 0.09) 0.12 
Length (L0, mm) 59 (SD 3.6) 61 (SD 3.3) 0.24 
CSA (cm2) 0.06 (SD 0.009) 0.07 (SD 0.013) 0.29 
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Figure 49. Spinotrapezius muscle force when stimulated at 80 Hz, and 40 Hz while 
breathing FIO2 of either 0.21 or 0.40 (p = 0.47, 0.21, and 0.04, respectively). 
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Figure 50. Relationship between oxygen consumption and muscle work, as 
measured by the force time integral (FTI) for all available points (p < 0.01; blue 
bands represent 95% confidence intervals). 
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Figure 51. Relationship between oxygen consumption and fatigue index (p = 0.48; 
blue bands represent 95% confidence intervals), where lower fatigue index indicates 
more fatigue. 
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Discussion 
 
Summary, limitations, and review of literature 
Overall, the most obvious and concerning issue in the present set of studies is the lack of 
a “true” control group.  The dependent groups in this study were the elastase and saline 
instilled animals.  Although one of the primary purposes of these investigations was to 
validate an animal model of skeletal muscle dysfunction in COPD, based on the proposed 
hypothesis, alterations in muscle structure and function would purportedly be due to 
chronic hypoxemia, not necessary attributed to the elastase-induced emphysema.  Thus, 
at the outset of the project, especially the phase II studies, it was expected that the 
elastase-induced emphysema (experimental) group would have significant hypoxemia, 
while the saline instilled group (control) would be normoxic; in the end, there was 
virtually no difference in PaO2 between groups when breathing room air (62 vs. 69 
mmHg, respectively).   
In addition to the possibly of a systemic viral respiratory infection, Rat respiratory virus, 
in most of my animals, other issues and limitations of this study include a possible 
hypotension related decrease in blood flow after administration of the FluoSpheres, 
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oxygen consumption values which are lower than predicted, as well as the wide 
variability in measures of muscle performance. 
Rat respiratory virus 
There is little-to-no publicly available information about Rat respiratory virus (RRV); 
what little that has been reported comes from the University of Missouri’s Research 
Animal Diagnostic Laboratory’s web site (Riley, Simmons et al. 2002) and a platform 
presentation from 2002 (Weisbroth 2002), which simply mentions RRV as an “emerging 
disease.”  Thus, whether the systemic hypoxemia found in my control animals is due to 
RRV, or some other infectious agent is not known; however, purportedly serological and 
histological data sent to the University of Missouri by VCU’s Division of Animal 
Resources from two rats in phase I of this study were indicative of RRV.   
RRV has purportedly been identified in research animals world wide.  Information from 
the University of Missouri (Riley, Simmons et al. 2002) (see web address in 
“Bibliography”) indicates that the pulmonary lesions peak at an age of 10-12 weeks, and 
by 18 weeks the lungs show signs of resolution.  Arterial blood gas data from phase I of 
the present study (Figure 26, page 93) seem to be consistent with these observations:  
while PaO2 in the elastase group stayed ≤ 80 mmHg for all age groups, PaO2 was low at 14 
at 18 weeks old (67 and 84 mmHg, respectively), by 22 weeks of age PaO2 had returned 
to normal (~100 mmHg).  It appeared that over time, the hypoxemia resolved, possibly 
along with the virus and pulmonary lesions.  In the meantime, VCU’s Division of Animal 
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Resources began housing the animals in an isolated room with filter-top cages for each 
animal, in an attempt to prevent air-borne spread of the virus from animal-to-animal.   
Thus, phase II in this series of investigations was initiated with the belief that 1) the 
filtered cages would minimize the spread and impact of the disease, 2) over time, 
systemic arterial PO2 would remain divergent between the elastase and saline groups, as 
any infected animals would recover prior to the terminal experiment, and 3) the 
hypothesis that chronic hypoxemia effects skeletal muscle oxygen transport and muscle 
performance could adequately be tested.  Unfortunately the gross necropsy and arterial 
blood gas results from phase II not only refute the contention that the animals get better, 
but rather it appears that their pulmonary infiltration worsens (sadly there are no 
pulmonary necropsy pictures from the phase I set of animals).   
For the elastase group, it is impossible to say how much of the hypoxemia was the result 
of emphysema as opposed to RRV.  However, it appears (Figures 34 and 35, pages 106 
and 107) that the lungs of the elastase group have less infiltrate and consolidation than 
the saline group.  While the PaO2/FIO2 ratio between groups was only slightly different 
(297 vs. 327 for the elastase and saline groups, respectively) when breathing room air, 
there was a significant difference when breathing supplemental oxygen (224 vs. 268).  
Perhaps this is due to more profound ventilation-perfusion mismatching in the 
emphysematous animals. 
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In addition to pulmonary infiltrates/consolidation, these animals seemed exquisitely 
sensitive to anesthesia.  Prior to continuous arterial pressure monitoring at the beginning 
of the surgery, at least a half-dozen pilot study animals died during the surgery or 
experiment while receiving the lowest recommended does of i.v. Saffan (0.294 ml/hr).  
The average Saffan dose to maintain a proper plane of anesthesia and a stable systemic 
mean arterial pressure (95 to 105 mmHg) was (0.13); a similar sensitivity was also noted 
with gas anesthesia (Isoflurane). 
MHC isoforms 
The proportion of soleus muscle MHC type I increased with age, while type IIa decreased 
and type IIb oscillated up and down (Figure 30, page 99).  The spinotrapezius muscle 
also demonstrated an increased proportion of MHC type I early on, but then a decrease to 
baseline by age 30 weeks, while MHC type IIa decreased early and stayed low, MHC 
type IIx increased, and type IIb oscillated up and down (Figure 31).  Although contrary to 
my original hypothesis, which was that the muscle would shift toward less oxidative 
fiber-types over time due to chronic hypoxia, it is possible that concomitant muscle fiber 
atrophy also occurred, which would result in a decrease oxygen demand.  However, there 
was no loss of muscle mass over time (Figure 21, page 87), and the muscle mass data 
were consistent with those of previous investigators in normal (Delp and Duan 1996) and 
chronically hypoxic rats (Deveci, Marshall et al. 2001).  
Delp and Daun reported that the spinotrapezius muscle was composed of 41% type I 
fibers, 7% type IIa, 17% type IIx, and 35% type IIb (Delp and Duan 1996), which is in 
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general agreement with an earlier study that, using slightly different methods, reported 
32% white fibers, 32% intermediate fibers, and 36% red fibers (Taylor and Calvey 1977).  
These prior data are somewhat consistent with the current results which found MHC 
isoforms I, IIa, IIx, and IIb in proportions of 16, 8, 45, and 30%, respectively (Table 7, 
page 98).  Since the experimental and control animals in the current study were equally 
hypoxemic, and there were no differences in MHC isoforms, no definitive conclusions 
can be made regarding possible fiber-type transformation.  However, it is possible that 
the hypoxemia experienced by both groups resulted in a shift towards more glycolytic 
fibers (IIa and IIx).  In that case, a decrease in type I and increase in type IIx proportions 
would be concordant with the proposed hypothesis, and may help explain the discrepancy 
between the current and previously published data.  
Of interest, and perhaps concern, is the fact that the values for soleus MHC type reported 
in Table 7 are drastically different than that of previous investigators in either normal rats 
(Delp and Duan 1996) or those exposed to short-term chronic hypoxia (Deveci, Marshall 
et al. 2001); these studies report that the soleus is composed of ~80% type I fibers as 
opposed the 9% found in the current study.  It is possible that either:  1) the severity of 
hypoxia in the current group of animals was so severe that their muscles were composed 
almost entirely of type II muscle fibers, or 2) the bands thought to represent the various 
MHC isoforms on the SDS-PAGE were improperly identified; neither scenario seems 
unlikely.  Deveci’s animals were breathing a PIO2 of ~85 mmHg, which should give a 
PaO2 of ~50 mmHg, at least as hypoxemic as the animals in the current study.  In the 
    
 
140
current SDS-PAGE analysis (Figures 28 and 29, page 97), if identification bands were 
shifted up (towards a higher molecular weight) three bands, so that the one currently 
labeled “IIx” would be MHC I, then the next, and only other significant, band would be 
MHC IIb, but there should be virtually no IIb in the soleus (Delp and Duan 1996).  A 
Western blot, using antibodies specific for MHC I, IIa, and IIb, revealed that this could 
be a possibility, especially if one assumes that separation of bands above the “new” type I 
was incomplete due to a lower than usual current used for electrophoresis (3.75 mA/gel 
as opposed to 15 mA/gel).  Of course, if this were the case, then it would also put the 
reasonable results of the spinotrapezius muscle into question, as the same scheme was 
used to evaluate both muscles. 
One study reported finding developmental MHC in the diaphragm of both patients with 
severe emphysema and control subjects (Nguyen, Shrager et al. 2000).  On a SDS-PAGE 
analysis, neonatal/embryonic MHC migrates intermediate to MHC I and MHC IIb, and 
could thus be a fifth band that could diminish the proportions of the other bands.  
However, this same study found that when normal protein concentrations were injected 
into each lane of the gel, there was not enough developmental MHC to produce a band 
with SDS-PAGE or to be stained during immunoblotting (Nguyen, Shrager et al. 2000); 
thus it is unlikely that there was a fifth band in the region of interest of the current study 
to confound the results.  
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Tween related hypotension  
Despite numerous reports regarding the hypotensive effect of Tween (Marks and Kolmen 
1971; Burnell and Maxwell 1974; Maxwell and Rencis 1974; Lorenz, Reimann et al. 
1977; Millard, Baig et al. 1977; Eschalier, Lavarenne et al. 1988; Munoz, Karila et al. 
1988), it is found in most fluorescent and radiolabeled microspheres which are marketed 
for blood flow measurements.  In one of the first studies of the hemodynamic effects of 
Tween-20, Marks and Kolmen (1971) found an immediate ~70 mmHg drop in mean 
arterial pressure in dogs given 5 ml of Tween-20.  In addition to hypotension, they also 
reported bradycardia and tachypnea, and found pretreatment with antihistamines 
prevented these effects.  This present study confirms that even minute amounts (0.002%) 
of Tween-20 can result in immediate, profound hypotension, but without bradycardia.  
Virtually eliminating the Tween, decreasing its percentage to ~5.6·10-5, as described in 
Appendix V was a simple and effective way of preventing this anaphylactic-like reaction, 
without administering prophylactic antihistaminic agents.   
Blood flow 
Several studies (Musch and Poole 1996; Poole, Musch et al. 1997; Kano, Padilla et al. 
2004) have measured ST blood flow by injecting 15-µm diameter radioactive 
microspheres with the animal at rest or during exercise, and then measuring the 
radioactivity of the ST after euthanization.  Using this method, blood flow to the entire 
muscle was measured and made relative to muscle mass, and gave values in the range of 
30 to 70 ml/min/100 g (Kano, Padilla et al. 2004). 
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Blood flow to the entire muscle was not measured in the current study, and thus flow was 
not reported in ml/min/100 g.  The results of this study are more comparable to those 
which report in vivo resting ST blood flows using the same ST preparation as in the 
present study (Lash 1994; Lash 1995; Lash and Bohlen 1995; Smith, Barbee et al. 2004); 
these studies report flows in the range of 6-10 nl/sec.  These values are approximately 
half of what the present study determined.  Smith et al’s (2004) blood velocities (3.4 to 
4.0 mm/sec) were virtual identical to the present study’s (3.4 to 3.9 mm/sec), but they 
were in smaller diameter arterioles (52 µm vs. 79 µm); this would account for the larger 
flow values of the current study.  Lash had similar size vessels (74 µm), but a different 
technique to measure velocity, dual-slit cross-correlation method, may have 
underestimated velocity in such large vessels (the method is traditionally used in venules, 
small arterioles, and capillaries).  Thus, when comparing the current data with these 
previous studies, in which PaO2 was normal, chronic hypoxemia does not appear to have a 
detrimental effect on ST blood flow.   
There are no known studies that have measured both arteriolar and venular flow 
concurrently, and thus no empirical data from which to predict this relationship.  The 
present study measured velocity and diameter of both arterioles and venules at nearly the 
same time in order to provide a measure of internal validity for the novel 
method/equations developed to measure blood velocity.  Figure 40 illustrated the 
relationship between arteriolar and venular flow.  While the best-fit line (red, slope 0.61) 
is close to the identity line (green, slope = 1) (r = 0.68), theoretically one would predict 
that they should be the same.  Several assumptions went into the derivation of Equations 
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17 and 18 (pages 71 and 72):  1) both vessels were perfectly cylindrical, 2) the velocity 
profile for both vessels was a Poiseuille parabolic profile (B = 1), and 3) all blood 
entering the ST muscle via the arteriole measured also left via the adjacent venule in 
which measurements were made.   
Each of these assumptions may not be entirely correct.  While the arterioles, which have 
a greater amount of smooth muscle, are likely cylindrical, the venules, which are more 
compliant, may assume a more elliptical cross section, which would affect diameter (d).  
This would lead to error in calculating both mean velocity (which uses W/d) and cross-
sectional area (πd2/4).  Although the velocity profile (B) may be different in arterioles 
and venules of different sizes (as in the current study), both objective (Pittman and 
Ellsworth 1986) and subjective (Schmid-Schoenbein and Zweifach 1975) data suggest 
that the profiles are similar in arterioles and venules of similar diameter, of which they 
were not in this study.  Of most concern is that there were two primary arterioles and 
venules in the spinotrapezius preparation used, thus allowing a different route for blood 
to enter or leave the muscle than from the measurement site.  Due to fewer assumptions 
for the arterioles as well as a lower variability in measurements, arteriolar flow was used 
for STQ  in all calculations and analyses.   
Oxygen consumption 
As seen in Table 16, the raw, un-normalized, values for spinotrapezius oxygen 
consumption in this study, 0.5 nl/sec, are consistent with those of a previous study from 
the same laboratory (Smith 2002).  However, Marshall and Davies (1999), reported a 
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resting oxygen consumption in the rat hind limb of 0.004 ml/min/g after normalizing for 
predicted muscle mass.  A nearly 20-fold lower value, 0.00026 ml/min/g, was calculated 
for spinotrapezius oxygen consumption when the current data were normalized to one-
third of spinotrapezius muscle mass (an approximation of the perfused muscle mass 
supplied by the large arteriole from which blood flow and oxygen measurements were 
made in this study).  Since there were two large arterioles in the field of view using the 
current preparation, in addition to the rostral feed artery and any vessels on the ventral 
surface of the preparation that are not observed, it is likely that the mass of tissue 
perfused in the current setup is much less than the one-third originally predicted (perhaps 
as little as one-sixth).  Since there is no way to estimate the exact perfused tissue mass, 
the current setup does not lend itself to “normalization.”  This was also evident when 
attempting to normalize the current raw blood flow data to muscle mass (see Table 16). 
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Table 16.  Resting systemic and tissue (spinotrapezius m.) parameters of oxygen 
delivery and consumption from the current study compared to reference values. 
Parameter Experimentally 
derived mean values 
Reference 
values 
Source for reference values 
CaO2 (systemic) 
(ml O2/dl of blood) 
14.6 (SD 1.0) 20 (Richardson, Leek et al. 2003) 
CaO2 (tissue) 
(ml O2/dl of blood) 
9.0 (SD 2.9)   
CvO2 (tissue) 
(ml O2/dl of blood) 
5.2 (SD 2.7)   
CaO2 – CvO2 (tissue) 
(ml O2/dl of blood) 
3.9 (SD 2.4) 3.5 – 5.0  
O2 extraction (tissue) 
rest 
exercise 
 
0.43 
0.42
 
(SD 0.21) 
(SD 0.23) 
 
0.20 
0.74 – 0.80
 
(Nellis, Flaim et al. 1980) 
(Nellis, Flaim et al. 1980; 
Henderson, Wagner et al. 2002) 
Blood flow (tissue) 
(dl of blood/min) 
1.05E-05 (SD 6E-06)   
Blood flow (tissue) 
(ml/min/100 g) 
0.800 (SD 0.50) 30 
60 
(Kano, Padilla et al. 2004) 
(Musch and Poole 1996) 
Oxygen consumption 
(nl O2/sec) 
0.5 (SD 0.3) 0.05 – 2.0 (Smith 2002) 
Oxygen consumption 
(ml O2/min) 
3.4·10-5 (SD 1.7·10-5)   
Oxygen consumption 
(ml O2/min/g of m.) 
0.00026 (SD 0.00014) 0.004 (Marshall and Davies 1999) 
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Of interest is the fact that while blood flow and oxygen consumption were higher in the 
saline group, oxygen extraction was higher in the elastase group (Table 13, page 127).  
Although all three of these parameters were statistically equivalent, these differences 
were consistent across time (time = 0, 3, and 8 min) and condition (FIO2 0.21 vs. 0.40), 
indicating that the difference was more real, and not merely by chance.  At rest the higher 
blood flow in the saline group was primarily due to larger diameter vessels, as blood 
velocity was equivalent (Table 11, page 119).  However, immediately after contraction, 
the vessel diameters were equivalent, but the blood velocity was higher in the saline 
group (Table 12).  Thus, the elastase group has both a more pronounced hyperemic 
response to exercise as well as having a higher degree of oxygen extraction, but blood 
velocity remained constant after exercise.  Perhaps the elastase group developed some 
degree of right heart failure and cardiac output was impaired compared to the saline 
group, and in an effort to compensate, peripheral skeletal muscles became more efficient 
at extracting oxygen. 
Based on Fick’s principle, mass conservation of oxygen (Equation 22), ST oxygen 
consumption ( STOV 2
 ) is the product of ST convective oxygen delivery (
2O
ST CaQ ⋅ ) and 
diffusive oxygen delivery, or oxygen extraction, (
222 OOO
CaCvCa − ). 
Equation 22 
( ) 


 −⋅⋅=
2
22
22
O
OO
O
STST
O Ca
CvCa
CaQV   
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Although STOV 2
  was still lower in the elastase group at all time points, it appears that while 
its convective oxygen delivery was diminished relative to the saline group, an  enhanced 
diffusive oxygen delivery helped the elastase group maintain a level of work and oxygen 
consumption comparable to that of the saline group (Figure 52, page 148).  Based on 
Equation 3, enhanced diffusive oxygen transport would be possible if there was either 1) 
an increase in area available for diffusion (A), or 2) a decrease in diffusion distance (∆r).  
Increased area available for diffusion could occur if there is an increase in capillary 
surface area due to increased capillarity of the muscle, while a decreased diffusion 
distance could occur if either capillarity truly increased, or if the muscle fibers were 
smaller.  Unfortunately no histological measures were done on the animals from this 
study; however, given that muscle mass and calculated CSA were slightly smaller for the 
elastase group (Table 15, page 131), this may partially account for the higher oxygen 
extraction. 
In a group of patients with COPD and activity matched controls, Richardson et al (2003) 
studied oxygen transport during a small-muscle mass exercise, similar to the present 
study, in which pulmonary function should not be a limiting factor.  For an equal 
workload, they did not find a difference in oxygen extraction, nor did they find a 
difference in capillarity or aerobic enzyme activity.  However, they did find a reduced 
capacity for muscular work that was associated with a reduced proportion of type I 
muscle fibers and an increase in type II, especially IIx. 
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Figure 52. Relationship between ST muscle oxygen consumption and work (FTI). 
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Muscle performance  
Only two other studies have measured muscle force of the spinotrapezius muscle.  Both 
Taylor and Calvey (1977), and Suzuki et al (1995) demonstrated that muscle force was 
partially fused at 40 Hz and became fully fused by 80 Hz, producing a maximal force of 
~0.44 N (45 g); data from the current study concur with these prior results (Figure 53).  
However, neither of these studies actually reports the raw force data or standard 
deviations from their experiments, but rather the value stated above was calculated from 
the representative force tracings in their figures.   
The force data from the current study exhibited a large degree of variability (Figure 54); 
mean peak force of the spinotrapezius muscle for all data points, when stimulated at 40 
Hz, was 51 mN (5.2 g) with a standard deviation of 36 mN (3.7 g); this variability is 
much greater than that reported by researchers in eye and tongue muscles (Goldberg, 
Wilson et al. 1997; Sutlive, Shall et al. 2000) as well as in the soleus muscle (Segal, 
Faulkner et al. 1986).  However, when the single outlier is removed from the data set, the 
mean force only decreases only 9.8%, to 46 mN, but the standard deviation decreases 
25%, to 27 mN.  This is still a wide degree of variability.  In an attempt to determine if 
this was due to the investigators inexperience at the beginning of the study, a scatterplot 
was done of all force data over time, Figure 54, which illustrates no learning effect of the 
investigator that resulted in less variable and/or increased force values over time.  Despite 
this variability and no statistically significant differences between groups, the saline 
group outperformed the elastase group in every measure of muscle performance (peak 
force at 80 and 40 Hz, force-time integral, and fatigue index).  As illustrated above, 
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Figure 52, STOV 2
  was also concomitantly decreased; it would have been interesting to see 
how these relationships compared at a different work loads (i.e., by increasing 
stimulation frequency > 40 Hz, or by increasing the pulse-train frequency > 1 Hz).   
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Figure 53. Representative isometric force profile of the spinotrapezius muscle 
stimulated at 10, 20, 40, and 80 Hz. 
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Figure 54. Scatterplot of force data over time, demonstrating no "learning effect" 
by the investigator (r = 0.12). 
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Suggestions for future research 
Above all else, the viral agent responsible for RRV needs to be characterized, a relatively 
non-invasive way in which to test animals for RRV needs to be developed, and an 
effective systematic and comprehensive prevention and control procedure needs to be 
developed.   
Due to the unknown effects of prolonged anesthesia as well as the variability in muscle 
force measures, it would be useful to know the intra-animal reliability of repeated 
measures of the course of an experiment under the same conditions in normal animals.  In 
addition, it would be useful to determine intra-animal reliability of repeated measures of 
blood velocity and blood flow under both steady state and exercise conditions. 
The stimulation protocol used did not result in a significant increase in STOV 2
  immediately 
after contraction.  A graded exercise protocol could help determine the relationship 
between ST STOV 2
  and muscle work as well as possibly define 
max2
ST
OV , so that future 
investigators would know more specifically what workload a given stimulation protocol 
would result in. 
As noted above, characterization of the spinotrapezius muscle histochemically with 
regard to muscle-fiber types, fiber cross-sectional area, and capillarity would provide 
useful information in interpreting the findings from the present study 
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Conclusions 
Due to a presumed Rat respiratory virus, which likely resulted in the control group 
(saline) being nearly as hypoxemic as the experimental group (elastase-induced 
emphysema), as well as a wide degree of variability in several independent measures, the 
present study was not able to definitively test the proposed hypothesis that chronic 
hypoxemia (due to emphysema) leads to both a diminished oxygen supply and demand in 
skeletal muscle. 
Compared to previous studies, animals with elastase induced emphysema also appeared 
to have a dramatic transformation of muscle fiber types away from oxidative and toward 
more glycolytic, especially type IIb.  However, these proportions were virtually the same 
as that seen in the control group which was normoxic 12 weeks after instillation, and 
increasing age actually lead to an small increase in MHC I (as seen in normal aging).   
Although many of the results of the present study were not statistically significant, they 
were consistent over time and are likely of physiological significance.  All measures of 
muscle performance were lower in the elastase group.  In addition, spinotrapezius oxygen 
consumption and blood flow were lower in the elastase group.  Only oxygen extraction 
was higher in the elastase group, likely due to diminished fiber cross-sectional area.  The 
addition of supplemental oxygen during isolated, small-muscle mass exercise did 
improve the force-time integral ~18% in both groups, suggesting that muscle work in 
these hypoxemic animals may be limited by oxygen supply.   
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Thus, the data on muscle fiber type, oxygen consumption and muscle performance 
suggests that elastase-induced emphysema in rats does lead to a similar skeletal muscle 
dysfunction that is seen in humans with COPD, and indicates that it is a valid animal 
model of skeletal muscle dysfunction in COPD.   
 
    
156 
Bibliography 
ALA (2001). Trends in chronic bronchitis and emphysema:  morbidity and mortality, 
American Lung Association Epidemiology & Statistics Unit. 
Anderson, R. (2001). Deaths: Leading causes 1999. National Vital Statistics Reports. 
Hyattsville, Maryland, National Center for Health Statistics. 49. 
Aniansson, A., G. Grimby, M. Hedberg and M. Krotkiewski (1981). Muscle morphology, 
enzyme activity and muscle strength in elderly men and women. Clinical 
Physiology 1(1): 73-86. 
Artigas, A., G. R. Bernard, J. Carlet, D. Dreyfuss, L. Gattinoni, L. Hudson, M. Lamy, J. 
J. Marini, M. A. Matthay, M. R. Pinsky, R. Spragg, P. M. Suter and t. C. 
Committee (1998). The American-European Consensus Conference on ARDS, 
Part 2. Ventilatory, Pharmacologic, Supportive Therapy, Study Design Strategies, 
and Issues Related to Recovery and Remodeling. Am. J. Respir. Crit. Care Med. 
157(4): 1332-1347. 
ATS/ERS (1999). Skeletal muscle dysfunction in chronic obstructive pulmonary disease. 
A statement of the American Thoracic Society and European Respiratory Society. 
Am J Respir Crit Care Med 159(4 Pt 2): S1-40. 
   157 
   
Aw, T. Y. and D. P. Jones (1990). Intracellular Respiration. The Lung:  Scientific 
Foundations. R. G. Crystal and J. B. West. New York, Raven Press, Ltd. 2: 1445-
1453. 
Bailey, J. K., C. A. Kindig, B. J. Behnke, T. I. Musch, G. W. Schmid-Schoenbein and D. 
C. Poole (2000). Spinotrapezius muscle microcirculatory function: effects of 
surgical exteriorization. Am J Physiol Heart Circ Physiol 279(6): H3131-3137. 
Behnke, B. J., M. D. Delp, P. McDonough, S. A. Spier, D. C. Poole and T. I. Musch 
(2004). Effects of chronic heart failure on microvascular oxygen exchange 
dynamics in muscles of contrasting fiber type. Cardiovasc Res 61(2): 325-332. 
Behnke, B. J., C. A. Kindig, T. I. Musch, S. Koga and D. C. Poole (2001). Dynamics of 
microvascular oxygen pressure across the rest-exercise transition in rat skeletal 
muscle. Respir Physiol 126(1): 53-63. 
Behnke, B. J., C. A. Kindig, T. I. Musch, W. L. Sexton and D. C. Poole (2002). Effects of 
prior contractions on muscle microvascular oxygen pressure at onset of 
subsequent contractions. J Physiol 539(Pt 3): 927-934. 
Berne, R. M. and M. N. Levy (1998). Physiology. St. Louis, Mosby. 
Bio-Rad PROTEAN II xi Cell and PROTEAN II xi 2-D Cell Instruction Manual. 2004. 
Bishop, J. J., P. R. Nance, A. S. Popel, M. Intaglietta and P. C. Johnson (2001). Effect of 
erythrocyte aggregation on velocity profiles in venules. Am J Physiol Heart Circ 
Physiol 280(1): H222-236. 
   158 
   
Bishop, J. J., A. S. Popel, M. Intaglietta and P. C. Johnson (2002). Effect of aggregation 
and shear rate on the dispersion of red blood cells flowing in venules. Am J 
Physiol Heart Circ Physiol 283(5): H1985-1996. 
Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 
72: 248-254. 
Brooke, M. H. and K. K. Kaiser (1970). Three "myosin adenosine triphosphatase" 
systems: the nature of their pH lability and sulfhydryl dependence. J Histochem 
Cytochem 18(9): 670-672. 
Burke, R. E., D. N. Levine, P. Tsairis and F. E. Zajac, 3rd (1973). Physiological types 
and histochemical profiles in motor units of the cat gastrocnemius. J Physiol 
234(3): 723-748. 
Burke, R. E., D. N. Levine and F. E. Zajac, 3rd (1971). Mammalian motor units: 
physiological-histochemical correlation in three types in cat gastrocnemius. 
Science 174(10): 709-712. 
Burnell, R. H. and G. M. Maxwell (1974). General and coronary haemodynamic effects 
of Tween 20. Aust J Exp Biol Med Sci 52(1): 151-156. 
Busch, R. H., R. L. Buschbom and L. G. Smith (1984). Comparison of methods for 
evaluation of experimentally induced emphysema. Environ Res 33(2): 473-496. 
Busch, R. H., K. E. Lauhala, S. M. Loscutoff and K. E. McDonald (1984). Experimental 
pulmonary emphysema induced in the rat by intratracheally administered elastase: 
morphogenesis. Environ Res 33(2): 497-513. 
   159 
   
Cassin, S., R. D. Gilbert, C. E. Bunnell and E. M. Johnson (1971). Capillary development 
during exposure to chronic hypoxia. Am J Physiol 220(2): 448-451. 
Costa, D. L., J. R. Lehmann, W. M. Harold and R. T. Drew (1986). Transoral tracheal 
intubation of rodents using a fiberoptic laryngoscope. Lab Anim Sci 36(3): 256-
261. 
Curran-Everett, D. and D. J. Benos (2004). Guidelines for reporting statistics in journals 
published by the American Physiological Society. J Appl Physiol 97(2): 457-459. 
Curran-Everett, D., S. Taylor and K. Kafadar (1998). Fundamental concepts in statistics: 
elucidation and illustration. J Appl Physiol 85(3): 775-786. 
Damon, E. G., J. L. Mauderly and R. K. Jones (1982). Early effects of intratracheal 
Instillation of elastase on mortality, Respiratory function, and pulmonary 
morphometry of F-344 rats. Toxicol Appl Pharmacol 64(3): 465-475. 
Delp, M. D. and C. Duan (1996). Composition and size of type I, IIA, IID/X, and IIB 
fibers and citrate synthase activity of rat muscle. J Appl Physiol 80(1): 261-270. 
Desplanches, D., H. Hoppeler, L. Tuscher, M. H. Mayet, H. Spielvogel, G. Ferretti, B. 
Kayser, M. Leuenberger, A. Grunenfelder and R. Favier (1996). Muscle tissue 
adaptations of high-altitude natives to training in chronic hypoxia or acute 
normoxia. J Appl Physiol 81(5): 1946-1951. 
Deveci, D., J. M. Marshall and S. Egginton (2001). Relationship between capillary 
angiogenesis, fiber type, and fiber size in chronic systemic hypoxia. Am J Physiol 
Heart Circ Physiol 281(1): H241-252. 
   160 
   
Eaton, T., J. E. Garrett, P. Young, W. Ferguson, J. Kolbe, S. Rudkin and Whyte (2002). 
Ambulatory oxygen improves quality of life in COPD patietns: a randomized 
controlled study. Eur Respir J 20(2): 306-312. 
Eichelbronner, O., A. Sielenkamper, M. D'Almeida, C. G. Ellis, W. J. Sibbald and I. H. 
Chin-Yee (1999). Effects of FIO2 on hemodynamic responses and O2 transport 
during RSR13-induced reduction in P50. Am J Physiol Heart Circ Physiol 277(1): 
H290-298. 
Engelson, E. T., G. W. Schmid-Schonbein and B. W. Zweifach (1985). The 
microvasculature in skeletal muscle. III. Venous network anatomy in 
normotensive and spontaneously hypertensive rats. Int J Microcirc Clin Exp 4(3): 
229-248. 
Engelson, E. T., G. W. Schmid-Schonbein and B. W. Zweifach (1986). The 
microvasculature in skeletal muscle. II. Arteriolar network anatomy in 
normotensive and spontaneously hypertensive rats. Microvasc Res 31(3): 356-
374. 
Engelson, E. T., T. C. Skalak and G. W. Schmid-Schonbein (1985). The 
microvasculature in skeletal muscle. I. Arteriolar network in rat spinotrapezius 
muscle. Microvasc Res 30(1): 29-44. 
Eriksson, S. (1965). Studies in alpha 1-antitrypsin deficiency. Acta Med Scand 117(Suppl 
432): 1-85. 
   161 
   
Eschalier, A., J. Lavarenne, C. Burtin, M. Renoux, E. Chapuy and M. Rodriguez (1988). 
Study of histamine release induced by acute administration of antitumor agents in 
dogs. Cancer Chemother Pharmacol 21(3): 246-250. 
Finlay, G. A., M. D. O'Donnell, C. M. O'Connor, J. P. Hayes and M. X. FitzGerald 
(1996). Elastin and collagen remodeling in emphysema. A scanning electron 
microscopy study. Am J Pathol 149(4): 1405-1415. 
Fisher, A. J., N. W. Schrader and B. Klitzman (1992). Effects of chronic hypoxia on 
capillary flow and hematocrit in rat skeletal muscle. Am J Physiol 262(6 Pt 2): 
H1877-1883. 
Goldberg, M. E. and C. W. Henry (2000). Guidelines of Acceptable Methods for 
Euthanasia of Animals, Virginia Commonwealth University Institutional Animal 
Care and Use Committee.  
(http://www.research.vcu.edu/dar/dar_guides/Acceptable_Methods_for_Euthanasi
a_of_Animals.pdf) 
Goldberg, S. J., K. E. Wilson and M. S. Shall (1997). Summation of extraocular motor 
unit tensions in the lateral rectus muscle of the cat. Muscle Nerve 20(10): 1229-
1235. 
Golub, A. S. and R. N. Pittman (2003). Thermostatic animal platform for intravital 
microscopy of thin tissues. Microvasc Res 66(3): 213-217. 
Golub, A. S., A. S. Popel, L. Zheng and R. N. Pittman (1997). Analysis of 
phosphorescence in heterogeneous systems using distributions of quencher 
concentration. Biophys J 73(1): 452-465. 
   162 
   
Gray, S. D. (1973). Rat spinotrapezius muscle preparation for microscopic observation of 
the terminal vascular bed. Microvasc Res 5(3): 395-400. 
Green, H. J., J. R. Sutton, A. Cymerman, P. M. Young and C. S. Houston (1989). 
Operation Everest II: adaptations in human skeletal muscle. J Appl Physiol 66(5): 
2454-2461. 
Green, H. J., J. R. Sutton, E. E. Wolfel, J. T. Reeves, G. E. Butterfield and G. A. Brooks 
(1992). Altitude acclimatization and energy metabolic adaptations in skeletal 
muscle during exercise. J Appl Physiol 73(6): 2701-2708. 
Gross, P., M. Babjak, E. Tolker and M. Kaschak (1964). Enzymatically produced 
pulmonary emphysema:  a preliminary report. J Occup Med 6: 481-4884. 
Gross, P., E. Pfitzer, E. Tolker and e. al (1965). Experimental emphysema:  Its production 
with papain in normal and silicotic rats. Arch Environ Health 11: 50-58. 
Hall, F. G. (1966). Minimal utilizable oxygen and the oxygen dissociation curve of blood 
of rodents. J Appl Physiol 21(2): 375-378. 
Hamilton, A., K. Killian, E. Summers and N. Jones (1995). Muscle strength, symptom 
intensity, and exercise capacity in patients with cardiorespiratory disorders. Am J 
Respir Crit Care Med 152: 2021-2031. 
Hansen-Smith, F., A. S. Greene, A. W. Cowley, Jr. and J. H. Lombard (1990). Structural 
changes during microvascular rarefaction in chronic hypertension. Hypertension 
15(6 Pt 2): 922-928. 
   163 
   
Henderson, K. K., H. Wagner, F. Favret, S. L. Britton, L. G. Koch, P. D. Wagner and N. 
C. Gonzalez (2002). Determinants of maximal O(2) uptake in rats selectively bred 
for endurance running capacity. J Appl Physiol 93(4): 1265-1274. 
Hildebrand, I. L., C. Sylven, M. Esbjornsson, K. Hellstrom and E. Jansson (1991). Does 
chronic hypoxaemia induce transformations of fibre types? Acta Physiol Scand 
141(3): 435-439. 
Honig, C. R., T. E. J. Gayeski and K. Groebe (1991). Myoglobin and Oxygen Gradients. 
The Lung:  Scientific Foundations. R. G. Crystal and J. B. West. New York, 
Raven Press, Ltd. 2: 1489-1496. 
Hoppeler, H., E. Kleinert, C. Schlegel, H. Claassen, H. Howald, S. Kayar and P. 
Cerretelli (1990). Morphological adaptations of human skeletal muscle to chronic 
hypoxia. Int J Sports Med 11(suppl 1): S3-S9. 
Hoppeler, H. and M. Vogt (2001). Muscle tissue adaptations to hypoxia. J Exp Biol 
204(Pt 18): 3133-3139. 
Howald, H., D. Pette, J. Simoneau, A. Uber, H. Hoppeler and P. Cerretelli (1990). Effect 
of chronic hypoxia on muscle enzyme activities. Int J Sports Med 11: 510-514. 
Hughes, R. L., H. Katz, V. Sahgal, J. A. Campbell, R. Hartz and T. W. Shields (1983). 
Fiber size and energy metabolites in five separate muscles from patients with 
chronic obstructive lung diseases. Respiration 44(5): 321-328. 
Icochea, A., B. S. Cooper and C. Kuhn (1982). The effect of oxygen on Cor pulmonale in 
experimental emphysema induced by elastase or elastase and beta-
aminopropionitrile in hamsters. Am Rev Respir Dis 126(5): 792-796. 
   164 
   
Institute of Laboratory Animal Resources (U.S.). Committee on Care and Use of 
Laboratory Animals. (1996). Guide for the Care and Use of Laboratory Animals. 
Bethesda, Md., U.S. Dept. of Health and Human Services Public Health Service 
National Institutes of Health. 
Itoh, K., T. Moritani, K. Ishida, C. Hirofuji, S. Taguchi and M. Itoh (1990). Hypoxia-
induced fibre type transformation in rat hindlimb muscles. Histochemical and 
electro-mechanical changes. Eur J Appl Physiol Occup Physiol 60(5): 331-336. 
Jakobsson, P., L. Jorfeldt and A. Brundin (1990). Skeletal muscle metabolites and fiber 
types in patients with advanced chronic obstructive pulmonary disease (COPD), 
with and without chronic respiratory failure. Eur Respir J 3: 192-196. 
Jakobsson, P., L. Jorfeldt and J. Henriksson (1995). Metabolic enzyme activity in the 
quadriceps femoris muscle in patients with severe chronic obstructive pulmonary 
disease. Am J Respir Crit Care Med 151: 374-377. 
Kano, Y., D. Padilla, K. S. Hageman, D. C. Poole and T. I. Musch (2004). Downhill 
running: a model of exercise hyperemia in the rat spinotrapezius muscle. J Appl 
Physiol: 00334.02004. 
Kaplan, P. D., C. Kuhn and J. A. Pierce (1973). The induction of emphysema with 
elastase. I. The evolution of the lesion and the influence of serum. J Lab Clin Med 
82(3): 349-356. 
Kindig, C. A., T. I. Musch, R. J. Basaraba and D. C. Poole (1999). Impaired capillary 
hemodynamics in skeletal muscle of rats in chronic heart failure. J Appl Physiol 
87(2): 652-660. 
   165 
   
Kindig, C. A. and D. C. Poole (1998). A comparison of the microcirculation in the rat 
spinotrapezius and diaphragm muscles. Microvasc Res 55(3): 249-259. 
Kindig, C. A. and D. C. Poole (1999). Effects of skeletal muscle sarcomere length on in 
vivo capillary distensibility. Microvasc Res 57(2): 144-152. 
Kindig, C. A. and D. C. Poole (2001). Sarcomere length-induced alterations of capillary 
hemodynamics in rat spinotrapezius muscle: vasoactive vs passive control. 
Microvasc Res 61(1): 64-74. 
Kindig, C. A., T. E. Richardson and D. C. Poole (2002). Skeletal muscle capillary 
hemodynamics from rest to contractions: implications for oxygen transfer. J Appl 
Physiol 92(6): 2513-2520. 
Kindig, C. A., W. L. Sexton, M. R. Fedde and D. C. Poole (1998). Skeletal muscle 
microcirculatory structure and hemodynamics in diabetes. Respir Physiol 111(2): 
163-175. 
Kinirons, S. A. (2002). The effects of an altered activity level, via artificial rearing, on 
the developing rat tongue retractor musculature. Anatomy/Physical Therapy. 
Richmond, VCU: 115. 
Kuhn, C., 3rd and F. Tavassoli (1976). The scanning electron microscopy of elastase-
induced emphysema. A comparison with emphysema in man. Lab Invest 34(1): 2-
9. 
Kuhn, C., S. Y. Yu, M. Chraplyvy, H. E. Linder and R. M. Senior (1976). The induction 
of emphysema with elastase. II. Changes in connective tissue. Lab Invest 34(4): 
372-380. 
   166 
   
Kunert, M. P., J. F. Liard, D. J. Abraham and J. H. Lombard (1996). Low-affinity 
hemoglobin increases tissue PO2 and decreases arteriolar diameter and flow in the 
rat cremaster muscle. Microvasc Res 52(1): 58-68. 
Lahiri, S. (1975). Blood oxygen affinity and alveolar ventilation in relation in body 
weight in mammals. Am J Physiol 229(2): 529-536. 
Lash, J. M. (1994). Contribution of arterial feed vessels to skeletal muscle functional 
hyperemia. J Appl Physiol 76(4): 1512-1519. 
Lash, J. M. (1995). Arterial and arteriolar contributions to skeletal muscle functional 
hyperemia in spontaneously hypertensive rats. J Appl Physiol 78(1): 93-100. 
Lash, J. M. (1998). Exercise training enhances adrenergic constriction and dilation in the 
rat spinotrapezius muscle. J Appl Physiol 85(1): 168-174. 
Lash, J. M. (1998). Training-induced alterations in contractile function and excitation-
contraction coupling in vascular smooth muscle. Med Sci Sports Exerc 30(1): 60-
66. 
Lash, J. M. and H. G. Bohlen (1987). Perivascular and tissue PO2 in contracting rat 
spinotrapezius muscle. Am J Physiol 252(6 Pt 2): H1192-1202. 
Lash, J. M. and H. G. Bohlen (1995). Excess oxygen delivery during muscle contractions 
in spontaneously hypertensive rats. J Appl Physiol 78(1): 101-111. 
Laurell, C. and S. Eriksson (1963). The electrphoretic alpha1-globulin pattern of alpha1-
anti-tyrpsin deficiency. Scand J Clin Lab Invest 15: 132-140. 
Lieber, R. L. (1992). Skeletal muscle structure and function : implications for 
rehabilitation and sports medicine. Baltimore, Williams & Wilkins. 
   167 
   
Lloyd, M. H. and S. E. Wolfensohn (1999). Practical use of distress scoring systems in 
the application of humane endpoints. Humane Endpoints in Animal Experiments 
for Biomedical Research: Proceedings of the International Conference, Zeist, The 
Netherlands, The Royal Society of Medicine Press: London, UK. 
Lorenz, W., H. J. Reimann, A. Schmal, P. Dormann, B. Schwarz, E. Neugebauer and A. 
Doenicke (1977). Histamine release in dogs by Cremophor E1 and its derivatives: 
oxethylated oleic acid is the most effective constituent. Agents Actions 7(1): 63-
67. 
Lucey, E. C., J. Keane, P.-P. Kuang, G. L. Snider and R. H. Goldstein (2002). Severity of 
Elastase-Induced Emphysema Is Decreased in Tumor Necrosis Factor-{alpha} 
and Interleukin-1{beta} Receptor-Deficient Mice. Lab Invest 82(1): 79-85. 
Lucey, E. C., J. J. O'Brien, Jr., W. Pereira, Jr. and G. L. Snider (1980). Arterial blood gas 
values in emphysematous hamsters. Am Rev Respir Dis 121(1): 83-89. 
MacDougall, J. D., H. J. Green, J. R. Sutton, G. Coates, A. Cymerman, P. Young and C. 
S. Houston (1991). Operation Everest II: structural adaptations in skeletal muscle 
in response to extreme simulated altitude. Acta Physiol Scand 142(3): 421-427. 
Maltais, F., P. LeBlanc, F. Whittom, C. Simard, K. Marquis, M. Belanger, M.-J. Breton 
and J. Jobin (2000). Oxidative enzyme activities of the vastus lateralis muscle and 
the functional status in patients with COPD. Thorax 55: 848-853. 
Maltais, F., A. Simard, C. Simard, J. Jobin, P. Desgagnes and P. LeBlanc (1996). 
Oxidative capacity of the skeletal muscle and lactic acid kinetics during exercise 
   168 
   
in normal subjects and in patients with COPD. Am J Respir Crit Care Med 153: 
288-293. 
Marks, L. and S. Kolmen (1971). Tween 20 shock in dogs and related fibrinogen 
changes. Am J Physiol 220(1): 218-221. 
Marshall, J. M. and W. R. Davies (1999). The effects of acute and chronic systemic 
hypoxia on muscle oxygen supply and oxygen consumption in the rat. Exp 
Physiol 84(1): 57-68. 
Mathieu-Costello, O., C. G. Ellis, R. F. Potter, I. C. MacDonald and A. C. Groom (1991). 
Muscle capillary-to-fiber perimeter ratio: morphometry. Am J Physiol 261(5 Pt 2): 
H1617-1625. 
Mattson, J. P. and D. C. Poole (1998). Pulmonary emphysema decreases hamster skeletal 
muscle oxidative enzyme capacity. J Appl Physiol 85(1): 210-214. 
Maxwell, G. M. and V. Rencis (1974). The effect of burimamide, an H-2 receptor 
antagonist, upon the general and coronary haemodynamics of intact dogs and 
upon histamine release by Tween 20. Aust J Exp Biol Med Sci 52(5): 825-832. 
McDonough, P., B. J. Behnke, C. A. Kindig and D. C. Poole (2001). Rat muscle 
microvascular PO2 kinetics during the exercise off-transient. Exp Physiol 86(3): 
349-356. 
Millard, R. W., H. Baig and S. F. Vatner (1977). Cardiovascular effects of radioactive 
microsphere suspensions and Tween 80 solutions. Am J Physiol 232(3): H331-
334. 
   169 
   
Moller, P., K. Hellstrom and I. L. Hermansson (1984). Myoglobin content in leg skeletal 
muscle in patients with chronic obstructive lung disease. Respiration 45(1): 35-
38. 
Munoz, A., P. Karila, P. Gallay, F. Zettelmeier, P. Messner, M. Mery and R. Grolleau 
(1988). A randomized hemodynamic comparison of intravenous amiodarone with 
and without Tween 80. Eur Heart J 9(2): 142-148. 
Musch, T. I. and D. C. Poole (1996). Blood flow response to treadmill running in the rat 
spinotrapezius muscle. Am J Physiol 271(6 Pt 2): H2730-2734. 
Narici, M. V. and B. Kayser (1995). Hypertrophic response of human skeletal muscle to 
strength training in hypoxia and normoxia. Eur J Appl Physiol Occup Physiol 
70(3): 213-219. 
NCHS (1999). Ambulatory care visits to physician offices, hospital outpatient 
departments and emergency departments:  United States, 1997. Vital Health Stat 
Series No 13 (143). 
Nellis, S. H., S. F. Flaim, K. M. McCauley and R. Zelis (1980). alpha-Stimulation 
protects exercise increment in skeletal muscle oxygen consumption. Am J Physiol 
Heart Circ Physiol 238(3): H331-339. 
Nguyen, T., J. Shrager, L. Kaiser, L. Mei, M. Daood, J. Watchko, N. Rubinstein and S. 
Levine (2000). Developmental myosin heavy chains in the adult human 
diaphragm: coexpression patterns and effect of COPD. J Appl Physiol 88(4): 
1446-1456. 
   170 
   
NOTTG (1980). Continuous or nocturnal oxygen therapy in hypoxemic chronic 
obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. 
Ann Intern Med 93(3): 391-398. 
Nusz, D. J., D. C. White, Q. Dai, A. M. Pippen, M. A. Thompson, G. B. Walton, C. J. 
Parsa, W. J. Koch and B. H. Annex (2003). Vascular rarefaction in peripheral 
skeletal muscle after experimental heart failure. Am J Physiol Heart Circ Physiol 
285(4): H1554-1562. 
O'Brien, J. J., Jr., E. C. Lucey and G. L. Snider (1979). Arterial blood gases in normal 
hamsters at rest and during exercise. J Appl Physiol 46(4): 806-810. 
Peter, J. B., R. J. Barnard, V. R. Edgerton, C. A. Gillespie and K. E. Stempel (1972). 
Metabolic profiles of three fiber types of skeletal muscle in guinea pigs and 
rabbits. Biochemistry 11(14): 2627-2633. 
Pierson, D. J. (2000). Pathophysiology and clinical effects of chronic hypoxia. Respir 
Care 45(1): 39-51; discussion 51-33. 
Pittman, R. N. (2000). Oxygen supply to contracting skeletal muscle at the 
microcirculatory level: diffusion vs. convection. Acta Physiol Scand 168(4): 593-
602. 
Pittman, R. N. (2004). Calculation of mean arteriolar velocity using FluoSpheres. J. D. 
Lowman, Jr. Richmond. 
Pittman, R. N. (2004). Calculation of mean venular blood velocity using FluoSpheres. J. 
D. Lowman, Jr. Richmond, VA. 
   171 
   
Pittman, R. N. and M. L. Ellsworth (1986). Estimation of red cell flow microvessels: 
consequences of the Baker-Wayland spatial averaging model. Microvasc Res 
32(3): 371-388. 
Poole, D. C. (2002). Reagrding elastase. J. D. Lowman, Jr. 
Poole, D. C., T. I. Musch and C. A. Kindig (1997). In vivo microvascular structural and 
functional consequences of muscle length changes. Am J Physiol 272(5 Pt 2): 
H2107-2114. 
Powell, R. J., G. W. Machiedo, B. F. Rush, Jr. and G. Dikdan (1991). Oxygen free 
radicals: effect on red cell deformability in sepsis. Crit Care Med 19(5): 732-735. 
Richardson, R. S. (1999). Skeletal muscle dysfunction vs. muscle disuse in patients with 
COPD. J Appl Physiol 86(5): 1751-1753. 
Richardson, R. S., B. T. Leek, T. P. Gavin, L. J. Haseler, S. R. D. Mudaliar, R. Henry, A. 
L. Ries, O. D. Mathieu-Costello and P. D. Wagner (2003). Reduced mechancial 
efficiency in COPD, but normal peak VO2 with small muscle mass exercise. Am. 
J. Respir. Crit. Care Med.: 200305-200627OC. 
Richardson, T. E., C. A. Kindig, T. I. Musch and D. C. Poole (2003). Effects of chronic 
heart failure on skeletal muscle capillary hemodynamics at rest and during 
contractions. J Appl Physiol 95(3): 1055-1062. 
Richmond, K. N., R. D. Shonat, R. M. Lynch and P. C. Johnson (1999). Critical PO(2) of 
skeletal muscle in vivo. Am J Physiol 277(5 Pt 2): H1831-1840. 
Riley, L. K., J. H. Simmons, G. Purdy, R. S. Livingston, C. L. Franklin, C. L. Besch-
Williford and R. J. Russell (2002). Rat Respiratory Virus (RRV).  Research 
   172 
   
Update: Idiopathic Lung Lesions in Rats.  
(http://www.radil.missouri.edu/RADILinfo/research/ResearchRRV.asp). 
Rome, L. C. and M. J. Kushmerick (1983). Energetics of isometric contractions as a 
function of muscle temperature. Am J Physiol Cell Physiol 244(1): C100-109. 
Rovainen, C. M., D. B. Wang and T. A. Woolsey (1992). Strobe epi-illumination of 
fluorescent beads indicates similar velocities and wall shear rates in brain 
arterioles of newborn and adult mice. Microvasc Res 43(2): 235-239. 
Russ, D. W., M. A. Elliott, K. Vandenborne, G. A. Walter and S. A. Binder-Macleod 
(2002). Metabolic costs of isometric force generation and maintenance of human 
skeletal muscle. Am J Physiol Endocrinol Metab 282(2): E448-457. 
Russell, J. A., C. A. Kindig, B. J. Behnke, D. C. Poole and T. I. Musch (2003). Effects of 
aging on capillary geometry and hemodynamics in rat spinotrapezius muscle. Am 
J Physiol Heart Circ Physiol 285(1): H251-258. 
Saltzman, D., F. A. DeLano and G. W. Schmid-Schonbein (1992). The microvasculature 
in skeletal muscle. VI. Adrenergic innervation of arterioles in normotensive and 
spontaneously hypertensive rats. Microvasc Res 44(3): 263-273. 
Sato, S., S. Kato, Y. Arisaka, H. Takahashi and H. Tomoike (1994). Pulmonary 
haemodynamics in awake rats following treatment with endotracheal pancreatic 
elastase. Eur Respir J 7(7): 1294-1299. 
Sato, S., S. Kato, H. Takahashi, Y. Arisaka and K. Takahashi (1990). Dose dependency 
of intratracheal elastase-induced changes in pressure volume curve and 
morphometry in rat lungs. Tohoku J Exp Med 161(2): 101-110. 
   173 
   
Satta, A., G. Migliori, A. Spanevello, M. Neri, R. Bottinelli, M. Canepari, M. Pellegrino 
and C. Reggiani (1997). Fiber types in skeletal muscles of chronic obstructive 
pulmonary disease patients related to respiratory function and exercise tolerance. 
Eur Respir J 10: 2853-2860. 
Schenkman, K. A., D. R. Marble, D. H. Burns and E. O. Feigl (1997). Myoglobin oxygen 
dissociation by multiwavelength spectroscopy. J Appl Physiol 82(1): 86-92. 
Schmid-Schoenbein, G. W. and B. W. Zweifach (1975). RBC velocity profiles in 
arterioles and venules of the rabbit omentum. Microvasc Res 10(2): 153-164. 
Schmid-Schonbein, G. W., G. Firestone and B. W. Zweifach (1986). Network anatomy of 
arteries feeding the spinotrapezius muscle in normotensive and hypertensive rats. 
Blood Vessels 23(1): 34-49. 
Schumacker, P. T. (1991). Systemic Effects of Hypoxia. The Lung: Scientific 
Foundations. W. J. Crystal Rg. New York, Raven Press, Ltd. 2: 1534-1551. 
Segal, S. S., J. A. Faulkner and T. P. White (1986). Skeletal muscle fatigue in vitro is 
temperature dependent. J Appl Physiol 61(2): 660-665. 
Serres, I., V. Gautier, A. Varray and C. Prefaut (1998). Impaired skeletal muscle 
endurance related to physical inactivity and altered lung function in COPD 
patients. Chest 113: 900-905. 
Severinghaus, J. W. (1966). Blood gas calculator. J Appl Physiol 21(3): 1108-1116. 
Sexton, W. L. and D. C. Poole (1998). Effects of emphysema on diaphragm blood flow 
during exercise. J Appl Physiol 84(3): 971-979. 
   174 
   
Sheridan, R. L., W. M. Zapol, R. H. Ritz and R. G. Tompkins (1999). Low-dose inhaled 
nitric oxide in acutely burned children with profound respiratory failure. Surgery 
126(5): 856-862. 
Sillau, A. H., L. Aquin, M. V. Bui and N. Banchero (1980). Chronic hypoxia does not 
affect guinea pig skeletal muscle capillarity. Pflugers Arch 386(1): 39-45. 
Skalak, T. C. and G. W. Schmid-Schonbein (1986). The microvasculature in skeletal 
muscle. IV. A model of the capillary network. Microvasc Res 32(3): 333-347. 
Slayter, E. M. (1970). Optical Methods in Biology. New York, Wiley-Interscience. 
Smith, K. and J. M. Marshall (1999). Physiological adjustments and arteriolar 
remodelling within skeletal muscle during acclimation to chronic hypoxia in the 
rat. J Physiol 521 Pt 1: 261-272. 
Smith, L., M. H. Tiba, M. E. Goldberg and R. W. Barbee (2004). Chronic implantation of 
transit-time flow probes on the ascending aorta of rodents. Lab Anim 38(4): 362-
370. 
Smith, L. M. (2002). Oxygen delivery to the skeletal muscle of the spontaneously 
hypertensive rat. Physiology. Richmond, Virginia Commonwealth University: 
144. 
Smith, L. M., R. W. Barbee, K. R. Ward and R. N. Pittman (2004). Prolonged reduction 
of tissue PO2 in the spinotrapezius muscle of spontaneously hypertensive rats 
following contraction. Am J Physiol Heart Circ Physiol: 00980.02002. 
   175 
   
Smith, L. M., R. W. Barbee, K. R. Ward and R. N. Pittman (2004). Prolonged tissue PO2 
reduction after contraction in spinotrapezius muscle of spontaneously 
hypertensive rats. Am J Physiol Heart Circ Physiol 287(1): H401-407. 
Smith, L. M., A. S. Golub and R. N. Pittman (2002). Interstitial PO(2) determination by 
phosphorescence quenching microscopy. Microcirculation 9(5): 389-395. 
Snider, G. L., E. C. Lucey and P. J. Stone (1986). Animal models of emphysema. Am Rev 
Respir Dis 133(1): 149-169. 
Snider, G. L. and C. B. Sherter (1977). A one-year study of the evolution of elastase-
induced emphysema in hamsters. J Appl Physiol 43(4): 721-729. 
Snider, G. L., C. B. Sherter, K. W. Koo, J. B. Karlinsky, J. A. Hayes and C. Franzblau 
(1977). Respiratory mechanics in hamsters following treatment with endotracrael 
elastase or collagenase. J Appl Physiol 42(2): 206-215. 
Streiner, D. L. (1996). Maintaining standards: differences between the standard deviation 
and standard error, and when to use each. Can J Psychiatry 41(8): 498-502. 
Sutlive, T. G., M. S. Shall, J. R. McClung and S. J. Goldberg (2000). Contractile 
properties of the tongue's genioglossus muscle and motor units in the rat. Muscle 
Nerve 23(3): 416-425. 
Suzuki, H., D. C. Poole, B. W. Zweifach and G. W. Schmid-Schonbein (1995). Temporal 
correlation between maximum tetanic force and cell death in postischemic rat 
skeletal muscle. J Clin Invest 96(6): 2892-2897. 
Swain, D. P. and R. N. Pittman (1989). Oxygen exchange in the microcirculation of 
hamster retractor muscle. Am J Physiol 256(1 Pt 2): H247-255. 
   176 
   
Takahashi, H., K. Kikuchi and H. Nakayama (1992). Effect of chronic hypoxia on 
skeletal muscle fiber type in adult male rats. Ann Physiol Anthropol 11(6): 625-
630. 
Talmadge, R. J. and R. R. Roy (1993). Electrophoretic separation of rat skeletal muscle 
myosin heavy-chain isoforms. J Appl Physiol 75(5): 2337-2340. 
Tangelder, G. J., D. W. Slaaf, A. M. Muijtjens, T. Arts, M. G. oude Egbrink and R. S. 
Reneman (1986). Velocity profiles of blood platelets and red blood cells flowing 
in arterioles of the rabbit mesentery. Circ Res 59(5): 505-514. 
Taylor, K. and T. N. Calvey (1977). Histochemical characteristics and contractile 
properties of the spinotrapezius muscle in the rat and the mouse. J Anat 123(1): 
67-76. 
Teisseire, B. P., C. D. Soulard, L. J. Teisseire, R. A. Herigault and D. N. Laurent (1984). 
Induced low P50 in anesthetized rats: blood gas, circulatory and metabolic 
adjustments. Respir Physiol 58(3): 335-344. 
Termin, A., R. S. Staron and D. Pette (1989). Myosin heavy chain isoforms in 
histochemically defined fiber types of rat muscle. Histochemistry 92(6): 453-457. 
van Ekeren, G. J., R. C. Sengers and A. M. Stadhouders (1992). Changes in volume 
densities and distribution of mitochondria in rat skeletal muscle after chronic 
hypoxia. Int J Exp Pathol 73(1): 51-60. 
Vovenko, E. P., A. S. Golub and R. N. Pittman (2002). Oxygen tension and blood 
velocity measurements in single cortical microvessels during normovolemic 
hemodilution. Journal of Vascular Research 39(S1): 71. 
   177 
   
Wang, X. N., T. J. Williams, M. J. McKenna, J. L. Li, S. F. Fraser, E. A. Side, G. I. Snell, 
E. H. Walters and M. F. Carey (1999). Skeletal muscle oxidative capacity, fiber 
type, and metabolites after lung transplantation. Am J Respir Crit Care Med 
160(1): 57-63. 
Waynforth, H. B. and P. A. Flecknell (1992). Experimental and Surgical Technique in 
the Rat. San Diego, Academic Press. 
Weibel, E. R. (1984). The Pathway for Oxygen:  Structure and Function in the 
Mammalian Respiratory System. Cambridge, Mass., Harvard University Press. 
Weibel, E. R. (2000). Symmorphosis:  On Form and Function in Shaping Life. 
Cambridge, Mass., Harvard University Press. 
Weisbroth, S. H. (2002). Emerging Diseases of Laboratory Rodents. Tribranch, 
American Association for Laboratory Animal Science Annual Meeting, 
Philadelphia, PA. 
West, J. B. (1997). Pulmonary pathophysiology--the essentials. Baltimore, Md., Williams 
& Wilkins. 
West, J. B. (1998). Pulmonary pathophysiology--the essentials. Baltimore, Md., Williams 
& Wilkins. 
Whittom, F., J. Jobin, P. Simard, P. LeBlanc, C. Simard, S. Bernard, R. Belleau and F. 
Maltais (1998). Histochemical and morphological characteristics of the vastus 
lateralis muscle in patients with chronic obstructive pulmonary disease. Med Sci 
Sports Exerc 30: 1467-1474. 
   178 
   
Zattara-Hartmann, M., M. Badier, C. Guillot, C. Tomei and Y. Jammes (1995). Maximal 
force and endurance to fatigue of respiratory and skeletal muscles in chronic 
hypoxemic patients: the effects of oxygen breathing. Muscle Nerve 18: 495-502. 
Zhang, K. M., L. D. Wright, P. Hu, J. A. Spratt, A. S. Wechsler and F. N. Briggs (1997). 
Induction of molecular and mechanical transformations in canine skeletal muscle 
by chronic neuromuscular stimulation. J Muscle Res Cell Motil 18(1): 81-90. 
Zheng, L., A. S. Golub and R. N. Pittman (1996). Determination of PO2 and its 
heterogeneity in single capillaries. Am J Physiol 271(1 Pt 2): H365-372. 
Zinchuk, V. V. and L. V. Dorokhina (2002). Blood Oxygen Transport in Rats under 
Hypothermia Combined with Modification of the -Arginine-NO Pathway. Nitric 
Oxide 6(1): 29-34. 
 
    
  179 
Appendix I.   
Thermostatic animal platform   
A thermostatic animal platform for intravital microscopy (Figures 55 and 56) was 
modified from one originally designed, built, and described by Aleksander S. Golub 
(Golub and Pittman 2003).  The current device was specifically designed for the 
spinotrapezius muscle, and incorporates a force transducer and tension adjuster for 
contractile measurement in skeletal muscle.  This device allows both transmission and 
episcopic illumination of thin tissues while maintaining both the animal and tissue at a 
physiologic temperature.  In addition, it allows muscle contractile measures to be made 
while the muscle is at its physiologic length and temperature; this is important, because 
muscle blood flow, contractile performance and metabolism decrease in response to sub-
physiologic temperatures.  A disclosure was made with the VCU Office of Technology 
Transfer, the device was assigned to the VCU-Intellectual Property Foundation, and it has 
been protected and is currently being marketed to potential licensees.  The following are 
the photographs, bill of materials, and detailed drawings of the device.
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Figure 55.  Thermostatic animal platform with force transducer and tension 
adjuster. 
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Figure 56.  Rat on thermostatic animal platform with spinotrapezius muscle 
connected to force transducer.   
   182 
   
Bill of materials 
I. Platform (Figure 57) 
A. Polymer Plastics Corp., http://www.polymerplastics.com/transparents_lexan.shtml  
1. Clear Lexan sheets 
a. Base (Figure 58) 
i. 11 x 9 x .250” (280 x 230 x 6mm) +/-0.010-0.029 $28.17 
b. Upright (Figure 59) 
i. 11 x 1.97 x .250” (280 x 50 x 6mm) +/-0.010-0.029 $18.66 
c. Window box (Figure 60) 
i. 1.260 x 10” (32 x 254.0mm), 0.093 +/-0.010-0.029 $17.85 
ii. 1.260 x 3” (32 x 76.2mm), 0.060 +/-0.010-0.029 $17.17 
iii. 1.220 x 8” (31 x 203.2mm), 0.030, +/-0.010-0.029 $27.28 
II. Animal heating tray  
A. VCU Custom Design and Fabrication 
1. L-shaped 1 mm thick aluminum, 80 x 250mm/30 x 250mm $15.00 
II. Animal heater: 
A. Minco Products, Inc., http://www.minco.com   
1. Standard Kapton heater 
a. 3 x 9”, 14.2Ω, 12” lead, PSA backing, no UL marking 
b. Part # HK5472R14.2L12B $129.10 
2. Heaterstat controller for standard Kapton heater# 1 above 
a. Part # CT698-1005T39CL1 
3. Neoprene foam insulation for #1 above  
a. Part # IN5176N1B(-) $5.00 
4. Window heater: 
   183 
   
a. Standard Thermal Clear Heater 
b. 0.9 x 2”, 43.3Ω, PSA backing, 12” lead 
c. Part # H6702R43.3L12B $117.75 
5. Heaterstat controller for window heater 
a. Part # CT698-1010T37CL1 
III. Optical window: 
A. Edmund Scientific, http://www.edmundoptics.com  
1. Window Glass 25 x 63.5 x1mm AR CTD 
a. Stock # NT32-739, Part # 32739 $14.90 
IV. Power supply 
A. Elpac Power Systems, http://www.elpac.com  
1. Power supply 
a. 100-120V AC input, 15.0V, 1.20A, 18W max output 
b. Part # WM1815/1.2-76 $42.09 
V. Other 
A. Miscellaneous size screws, thumb nuts, DC power connector, plastic box to 
contain electronics, 5 x 5mm acrylic rod, spring for width adjuster, E6000 
Industrial Strength Adhesive ((clear) Eclectic Products, Inc.), and foam for 
pedestal insulation ≈ $30.00 
Total cost  ≈ $460.00 
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Appendix II.   
Distress scoring sheet 
Table 17.  Distress scoring sheet.  Adapted from Lloyd and Wolfensohn’s work 
(1999), validating this distress scoring system with respiratory parameters with the 
elastase-induced emphysema model in the rat. 
Parameter Descriptive characteristic Score 
Appearance Normal 0 
 General lack of grooming 1 
 Piloerection, fresh ocular and nasal discharges 2 
 Piloerection, hunched up 3 
 Above and eyes half closed 4 
   
Natural behavior Normal 0 
 Minor changes 1 
 Less mobile and isolated, but alert 2 
 Restless or very still, not alert 3 
   
Hydration status Normal 0 
 Abnormal skin pinch test 5 
   
Clinical signs Normal Respiratory rate and pattern 0 
 Slight changes, increased rate only 1 
 Increased rate with abdominal breathing 2 
 Decreased rate with abdominal breathing 3 
 Marked abdominal breathing and cyanosis 4 
   
Provoked behavior Normal 0 
 Minor depression or exaggerated response 1 
 Moderate change in expected behavior 2 
 Very weak and precomatose 3 
   
Total  0-19 
   
Animals scoring ≥ 12/19 will be euthanized  
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Appendix III.   
Preparation of Albumin-bound Pd-porphyrin phosphorescence 
probe 
General precautions 
Use proper personal protective equipment and procedures: 1) respirator, when using 
powdered chemicals, 2) safety glasses, 3) gloves, and 4) wash any skin thoroughly if 
contaminated. 
Solubilization of Pd-porphyrin 
Table 18.  Ingredients for 20 ml phosphorescence probe (10 mg/ml) 
Item Quantity 
Tris base 1 g
BSA 1.32 g
Pd-MTCPP 200 mg
DMSO 4-5 ml
Deionized H2O 100 ml, divided
Table 19.  Solubilization – equipment and supplies 
Scale 10 ml beaker Mortar & pestle 
pH meter 30 ml beaker Mug (“don’t”) 
Stirrer & micro stirring bar 25 ml graduated cylinder Parafilm  
Spatula & small weigh boats Glass pipette & bulb Aluminum foil 
1. Prepare 2.75 M Tris base solution: 
a. Dissolve Tris into 3 ml of deionized H2O in 10 ml beaker.   
b. Cover with parafilm.   
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2. Prepare 1 mM BSA solution: 
a. Poor 20 ml of deionized H2O into a 30 ml beaker with micro-stir bar. 
b. With beaker on stirrer, use spatula to slowly add small portions of BSA 
(just sprinkle enough to cover the surface, letting each application 
dissolve).  This takes at least 60 minutes. 
c. Use pipette to add a few drops of Tris base as needed to keep pH between 
7.3 and 7.7. 
d. Color should gradually turn a clear yellow by the completion of this step. 
3. In meantime, gently crush granules of Pd-MTCPP into mortar with pestle until 
you have a fine powder (wear respirator).   
4. Slowly add small portions of Pd-MTCPP to BSA solution on the stirrer (just 
sprinkle enough to cover the surface, letting each application dissolve).  
a. This will take ~30 minutes. 
b. Protect solution from light, wrap beaker with aluminum foil.   
c. Rinse excess Pd-MTCPP from mortar and pestle with few drops of 
DMSO, and poor into beaker; rinse a second time.   
d. Maintain pH between 7.3 and 7.7 with drops of Tris base.   
e. Cover with “don’t” mug and leave Pd-porphyrin solution on stirrer 
overnight. 
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Dialysis of Pd-porphyrin 
Table 20.  Ingredients for 1 L of dialysis solution 
Item Quantity
PBS 1 packet
PVP 55 g
Deionized H2O 1 L
Table 21.  Dialysis – equipment and supplies 
Large weigh boats 10 ml beaker 
Large stir bar 3 Spectra/Por® 4 membranes, 10 cm long 
1 L beaker Spectra/Por® clamps (3 white, 3 orange) 
600 ml beaker Plastic forceps & small needle 
Two 100 ml beakers with deionized H2O Large glass syringe with Teflon needle 
1. Prepare 1 mM dialysis solution: 
a. Dissolve PBS into 1 L of deionized H2O. 
b. Fill 10 ml beaker with PBS (for volume restoration) 
c. Heat remaining PBS buffer solution to approximately 50° C on stirrer. 
d. Slowly add PVP to PBS buffer solution (wear respirator).  It takes ~60 
minutes to dissolve completely. 
2. Poor 500 ml of dialysis solution into 600 ml beaker, and cover remaining beaker 
with parafilm. 
3. Prepare dialysis bags: 
a. Place one Spectra/Por® 4 membrane into 100 ml beaker with deionized 
H2O, let sit for 5 minutes. 
b. In meantime, withdraw Pd-porphyrin solution into syringe. 
c. Clamp one end of membrane with white/weighted clamp. 
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d. Open other end gently with small needle, and inject ~8 ml of Pd-porphyrin 
solution using glass syringe with Teflon needle. 
e. Place orange clamp on other end of membrane, while leaving some air at 
top. 
f. Rinse in a separate 100 ml beaker with deionized H2O. 
g. Place “bag” into dialysis solution.  
h. Repeat for 2nd and 3rd membrane 
4. Cover beaker on stirrer with aluminum foil, and let dialyze overnight (18 to 20 
hours). 
5. Remove bags from beaker and replace “old” dialysis solution with remaining 
dialysis solution. 
6. Leave solution on stirrer for 4 – 6 hours, or longer. 
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Final processing 
Table 22.  Final processing – equipment and supplies 
100 ml beaker with deionized H2O Vacuum pump 
Two 50 ml beakers 50 – 0.5 ml microcentrifuge tubes with cap 
25 ml graduated cylinder Pipette and sterile pipette tip 
115-ml sterilization filter unit Dewar and 4” liquid N2 
< 10 ml PBS (from “Dialysis,” step 1b)  
1. Remove dialysis bags from solution, rinse in 100 ml beaker with deionized H2O, 
and dry with Kimwipe.  
2. Unclamp dialysis bag and pour contents into 50 ml beaker, and squeeze remaining 
solution out. 
3. Measure volume of solution in graduated cylinder. 
4. Using vacuum pump, filter solution through sterilization filter unit, and return to a 
clean 50 ml beaker. 
5. Rinse the graduated cylinder, original beaker, and filter unit with enough PBS to 
increase to volume measured in step 3 to 20 ml. 
6. Pipette out 0.5 ml of solution into microcentrifuge tubes and close cap tightly. 
7. Drop into liquid N2 filled dewar. 
8. Store in -80° C freezer, room 3-012. 
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Usage 
Table 23.  Usage – equipment and supplies 
20-G needle, 22 mm long with blunt tip 
1 ml empty syringe with Luer-Lok tip 
One 0.5 ml microcentrifuge tube of probe 
1 ml syringe filled with PBS 
 
1. Remove a 0.5 ml microcentrifuge tube of Pd-porphyrin phosphorescence probe 
from freezer and thaw at room temperature. 
2. Using 20-G needle and syringe, slowly withdraw solution from microcentrifuge 
tube (avoid bring any air bubbles into solution). 
3. Inject into animal via stopcock and catheter 
4. Flush “probe” syringe with 0.5 ml PBS, then inject into animal. 
5. Flush catheter with 0.3 to 0.4 ml PBS. 
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Bill of materials 
Table 24.  Pd-porphyrin – bill of materials for 20 ml of probe 
Item Product 
number 
Common 
abbreviation
Supplier MW Quantity
Oxyphor R0 
(Pd-meso-tetra 
(4-carboxylphenyl) 
porphyrin) 
 
 Pd-MTCPP Oxygen Enterprises, Ltd., 
Philadelphia, PA 
896 200 mg 
Trizma ® base 
(CH2OH)3CNH2 
 
T-1503 Tris Sigma-Aldrich, Inc.,  
St. Louis, MO 
121.14 1 g 
Dimethyl sulfoxide 
(CH3)2SO 
 
D-8779 DMSO Sigma-Aldrich, Inc.,  
St. Louis, MO 
78.13 4-5 ml 
Albumin bovine 
serum, 
Fraction V 
 
A-9647 BSA Sigma-Aldrich, Inc.,  
St. Louis, MO 
66,000 1.32 g 
Polyvinylpyrrolidone 856568 PVP Sigma-Aldrich, Inc.,  
St. Louis, MO 
 
55,000 55 g 
Phosphate buffered 
saline (0.01 M), pH 
7.4 
 
P-3813 PBS Sigma-Aldrich, Inc.,  
St. Louis, MO 
 1 packet 
Spectra/Por ® 4 
dialysis membrane 
 
132700  Spectrum Laboratories, Inc., 
Rancho Dominquez, CA 
 3, 10 cm 
long 
Spectra/Por ® closures 132751  Spectrum Laboratories, Inc., 
Rancho Dominquez, CA 
 
 3 white/ 
3 orange 
115-ml sterilization 
filter unit 
 
121-0020  NALGENE Co.,  
Rochester, NY 
 1 
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Appendix IV.   
Molecular biology solutions and mixtures 
Agents used in the electrophoresis procedures were electrophoretic grade (Bio-Rad). 
MHC extraction solution 
The MHC extraction solution (pH 6.5) had a final composition of 0.3 M NaCl, 0.15 M 
Na2HPO4 and 10 mM EDTA, and was stored at 4° C.   
SDS-polyacrylamide gels 
The 8% separating gel was composed of the following stock solutions:  68.16% glycerol, 
29% acrylamide-bis (2%C), 1.5 M Tris (pH 8.8), 1 M glycine, 10% SDS, which were 
degassed for 15 minutes prior to initiation of polymerization with 10% ammonium 
persulfate (made fresh) and N,N,N’,N’-tetramethylethylenediamine (TEMED).   
The 4% stacking gel was composed of the following stock solutions:  68.16% glycerol, 
29% acrylamide-bis (2%C), 0.5 M Tris (pH 6.8), 100 mM EDTA, 10% SDS, as well as 
deionized water, which were degassed for 15 minutes prior to initiation of polymerization 
with 10% ammonium persulfate (made fresh) and TEMED.   
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Buffer solutions 
The sample buffer (2x Laemli) was composed of the following solutions:  0.5 Tris-HCl 
base, 10% SDS, 68.16% glycerol, 2 β-mercaptoethanol, and 0.05% bromophenol blue 
dye. 
The upper running buffer had a final composition of 100 mM Tris base, 150 mM glycine, 
and 0.1% SDS in deionized water; the lower running buffer was half as concentrated as 
the upper.  Both solutions were made immediately before gel electrophoresis and were 
stored at 4° C. 
Staining procedure solutions 
The fixative enhancer solution had a final composition of 50% methanol, 10% acetic 
acid, 10% fixative enhancer concentrate (Bio-Rad), and 30% deionized, distilled water. 
The staining solution was made with 1) silver complex solution, 2) reduction moderator 
solution, 3) image development reagent, and 4) development accelerator solution (Silver 
Stain Plus, Bio-Rad). 
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Appendix V.   
Preparation of FluoSpheres 
Dilution of FluoSpheres 
The 2.0 µm diameter FluoSpheres (F-8823, Carboxylate-Modified Microspheres, 
Molecular Probes, Inc., Eugen OR) had an original concentration of 4.5·109 particles/ml 
in an aqueous suspension with 0.02% Tween-20 and 2 mM sodium azide.  The goal 
concentration for injection was 4.5·108 particles/ml.  In addition to a 10-fold dilution, due 
to the histaminergic properties of Tween, the particles were “washed” as described below 
to yield 3-ml of solution (enough for 2-3 experiments).  This is best done immediately 
prior to an experiment, no more than 48 hours before. 
1. With the lid on tight, place the vial of FluoSpheres in an ultrasonic water bath for 
five minutes. 
2. Put micro-stir bar in vial, place vial on stirrer for at least five minutes (cover to 
protect from light). 
3. Pipette 0.3 ml of the probe into a small translucent plastic bottle and then add 2.7 
ml of normal saline. 
4. Centrifuge for 20 minutes at 3,600 rpm (~1,000 g). 
5. Withdraw 2.5 ml of supernatant and replace it with normal saline. 
6. Centrifuge again for 20 minutes at 3,600 rpm (~1,000 g). 
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7. Withdraw 2.5 ml of supernatant and replace it with normal saline. 
8. Place back on stirrer or in vortex mixer to re-suspend the particles 
This should reduce the Tween-20 concentration to ~5.6·10-5%, while maintaining a 
particle concentration of ~4.5·108 per ml.  
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Usage 
Prior to use in an experiment: 
1. Place the vial of diluted solution in the ultrasonic bath for five minutes. 
2. Use vortex mixer to re-suspend particles 
3. Withdraw 0.6 to 1.0 ml of solution into a 1-ml syringe, and cap (leaving some 
room for air). 
4. Immediately prior to injecting into the animal, briefly place the syringe in the 
vortex mixer. 
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